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Minutes of the Meeting 
 
The Department of Health and Human Services (HHS) and the Centers for Disease Control and 
Prevention (CDC) National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
(NCHHSTP) Division of Tuberculosis Elimination (DTBE) convened a meeting of the Advisory 
Council for the Elimination of Tuberculosis (ACET).  The proceedings were held on July 14-15, 
2009 in Building 8 of CDC’s Corporate Square Offices, Conference Room A/B/C in Atlanta, 
Georgia. 
 
 
 
 
 
Dr. Hazel Dean, Deputy Director of NCHHSTP and Designated Federal Official of ACET, called 
the meeting to order at 8:32 a.m. on July 14-15, 2009.  She welcomed the attendees to the 
proceedings and particularly recognized the new and alternate ex-officio and liaison members. 
  
Dr. Dean announced that ACET meetings are open to the public and all comments made during 
the proceedings are a matter of public record.  She emphasized that ACET members should be 
mindful of potential conflicts of interest identified by the CDC Committee Management Office 
and recuse themselves from participating in discussions or voting on issues in which they have 
a real or perceived conflict. 
 
Dr. Michael Fleenor, Chair of ACET, joined Dr. Dean in welcoming the attendees to the meeting 
and opened the floor for introductions.  The list of participants is appended to the minutes as 
Attachment 1. 
 
Opening Session 
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Dr. Dean presented the update on behalf of Dr. Kevin Fenton, Director of NCHHSTP, who was 
unable to attend the meeting.  Kathleen Sebelius, the new HHS Secretary, visited CDC and 
Agency for Toxic Substances and Disease Registry staff on May 5, 2009.  William Corr was 
appointed as the Deputy Secretary of HHS. 
 
The President committed to collaborating with Congress to pass comprehensive health reform 
in 2009.  HHS assisted in coordinating a major White House Forum on Health Reform on March 
5, 2009 as well as five Regional Health Forums across the country in March and April 2009.  A 
priority initiative in the American Recovery and Reinvestment Act (ARRA) is to advance the 
development of a nationwide interoperable health information technology (HIT) infrastructure 
and accelerate the adoption of HIT.  A critical component of this effort will be to ensure the 
private and security of patient information. 
 
Comparative effectiveness research (CER) will be conducted to provide information on the 
relative strengths and weaknesses of different medical interventions.  Under ARRA, $300 million 
was allocated to the Agency for Healthcare Research and Quality (AHRQ), $400 million was 
allocated to the Office of the Secretary, and $400 million was allocated to the National Institutes 
of Health (NIH).  CDC is engaged in discussions and the decision-making process related to 
CER, but CER funds are not expected to be allocated to CDC.  However, CDC will use the 
existing Leader-to-Leader mechanism the HHS agencies previously established to engage 
AHRQ in discussions regarding the allocation of CER funds at both the CDC and NCHHSTP 
levels.  ARRA requires all CER funds to be obligated by the end of FY2009. 
 
The President signed an Executive Order on March 9, 2009 to lift the ban on federal funding for 
promising human embryonic stem cell research.  The Executive Order directed NIH to draft 
guidelines that are both scientifically worthy and responsibly and ethically conducted. 
 
Dr. Thomas Frieden was appointed as the new CDC Director and assumed his position in June 
2009.  Dr. Frieden was the Commissioner of the New York City Department of Health and 
Mental Hygiene and was employed by CDC for 12 years.  He began his career at CDC as an 
Epidemic Intelligence Service Officer in 1990 and then led CDC’s TB control program in India 
for five years.  Dr. Frieden named Louis Salinas as CDC’s acting Chief of Staff.  Mr. Salinas 
previously served as Deputy Director of both the Division of Oral Health and Division of 
Adolescent and School Health. 
 
Dr. Frieden established the following key priorities for CDC:  (1) strengthen epidemiology and 
surveillance; (2) improve effectiveness to support partners at state, local and city levels; and (3) 
provide leadership in the areas of health reform, community prevention to further reduce the 
burden from the leading preventable causes of illness and death, and global health. 
 
According to the World Health Organization (WHO), >70 countries officially reported cases of 
novel influenza A (H1N1) infection.  WHO’s elevation of the pandemic alert level to Phase 6 on 
NCHHSTP Director’s Report 
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June 11, 2009 reflected the spread rather than the severity of illness.  Phase 6 indicated a 
global pandemic is underway.  CDC’s goals for the H1N1 response are to reduce the spread 
and severity of illness and provide information to help healthcare providers, public health 
officials and the public in addressing the challenges posed by this new public health threat.  
NCHHSTP accounted for 188 of 1,500 CDC staff members who responded to the pandemic. 
 
A weekly influenza surveillance report showed that all states reported H1N1 cases.  As of the 
week ending on July 4, 2009, nine states reported geographical widespread influenza activity, 
12 states and Puerto Rico reported influenza activity, ten states and the District of Columbia 
reported local influenza activity, 18 states reported sporadic influenza activity, and one state did 
not report influenza activity. 
 
Scientists in the Division of HIV/AIDS Prevention collaborated with colleagues to publish 
recommendations for protective behaviors relative to the novel H1N1 influenza virus for persons 
with HIV infection.  The recommendations provided guidance on symptom recognition, 
treatment, self-protective measures, adherence to currently prescribed medication for HIV 
infection, and chemoprophylaxis for HIV-positive close contacts of persons with H1N1 infection.  
The guidance noted that HIV-positive persons do not appear to be at elevated risk for influenza 
infection, but might be susceptible to greater complications if infected.  The recommendations 
were posted on the CDC web site at www.cdc.gov/h1n1flu/hiv_flu.htm. 
 
The Senate Committee on Health, Education, Labor and Pensions released a draft health 
reform bill on June 9, 2009, but the mark-up has not been completed at this time.  The 
committee proposed a $10 billion prevention trust fund and listed new programs, but did not 
allocate funding to specific programs.  The Senate Finance Committee has not yet publicly 
released its draft. 
 
The House Ways and Means, Energy and Commerce, and Education and Labor Committees 
released a draft health reform bill on June 19, 2009 that will be revised later in the week and 
then marked-up.  The three committees proposed $15.2 billion over five years in prevention 
spending and allocated funding to specific programs.  The majority of this funding would be 
dedicated to grants that support preventive services and state infrastructure development. 
 
Both the Senate and House bills authorize activities by the U.S. Preventive Services Task Force 
and the Community Preventive Services Task Force with the House bill calling for annual 
funding of $30 million for the Task Forces.  Both the Senate and House bills proposed the 
creation of a National Prevention Strategy to guide research and grant-making.  The Senate bill 
proposed the establishment of a “Prevention Council” with cabinet secretaries and other high-
level officials across the Executive Branch to oversee strategy development. 
 
The President’s 2010 budget of approximately $1 billion for NCHHSTP reflects approximately 
$54 million above the FY2009 Omnibus.  Of the approximately $54 million increase, ~$3 million 
would be targeted to pay increases and $51 million would be targeted to pay increases.  Of the 
proposed budget of approximately $1 billion for NCHHSTP, approximately $144 million would 
be allocated to TB, approximately $745 million would be allocated to domestic HIV/AIDS, 
approximately $18 million would be allocated to viral hepatitis, and approximately $153 million 
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would be allocated to STDs.  The proposed allocation of approximately $745 million for 
domestic HIV/AIDS reflects an increase of approximately $53 million above the FY2009 
Omnibus to focus on high-risk populations. 
 
NCHHSTP is continuing to develop its strategic plan with the following priorities:  a core mission 
of preventing and controlling HIV, viral hepatitis, STDs and TB; program collaboration and 
service integration; health equity; global health protection and systems strengthening; 
partnerships; and workforce development and capacity building.  NCHHSTP will solicit input on 
its strategic plan from ACET and other external partners later in the summer of 2009. 
 
NCHHSTP and the Coordinating Center for Infectious Diseases co-hosted the “Corrections and 
Public Health Consultation: Expanding the Reach of Prevention” in March 2009.  The 
consultation served as an opportunity for community partners and subject-matter experts from 
corrections, public health and academia to develop effective strategies to address health 
disparities and other issues related to TB, HIV/AIDS, viral hepatitis and STDs among the 
incarcerated population.  A summary of the corrections consultation will be posted on the CDC 
website. 
 
The summary report of the Social Determinants of Health (SDH) Consultation, convened by 
CDC with external partners in December 2008, was published in June 2009.  The report, 
Addressing Social Determinants of Health: Accelerating the Prevention and Control of 
HIV/AIDS, Viral Hepatitis, STD and TB, suggests both long- and short-term priorities to achieve 
this goal. The report is available on CDC’s new SDH web page at 
www.cdc.gov/socialdeterminants with links to SDH resources both within and outside of CDC.  
CDC welcomes comments and suggestions to improve the effectiveness of the SDH website. 
 
Dr. Kenneth Castro, Director of DTBE, emphasized the need for CDC to strengthen its 
partnership with AHRQ as funds are allocated to conduct CER projects.  This collaboration 
would ensure that CDC has an influential role in the implementation of CER projects to advance 
the overall public health mission. 
  
 
 
 
 
Dr. Kenneth Castro covered the following areas in his update.  The CDC Procurement and 
Grants Office allowed DTBE to structure the FY2010 TB cooperative agreements as a 
competitive continuation cycle to enable state health departments to use unobligated year-end 
dollars.  The funding opportunity announcement was posted on www.grants.gov on June 28, 
2009 with an application deadline of August 28, 2009.  The TB funding formula that was 
previously presented to ACET will be used in the FY2010 TB cooperative agreements.   
 
DTBE will offer training to healthcare personnel (HCP) in state and local health departments, 
territories and Pacific Islands to accurately use the revised report verified case of TB (RVCT) 
form.  Training will be targeted to HCP who collect data from patients, complete the RVCT form, 
enter data from the RVCT form into a data system, monitor the accuracy of TB program data 
DTBE Director’s Report 
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collection, and analyze data from the RVCT form.  Most of the country was covered with the 
initial training and the 14 remaining states will receive training in September 2009.  The RVCT 
self-study module will be available online at www2a.cdc.gov/TCEonline in late July 2009. 
 
DTBE’s other recent activities since the previous ACET meeting are highlighted as follows.  
Outbreak assistance was provided in response to requests from state and local health 
departments in Georgia and Florida in May-June 2009.  The external review of the 
Mycobacteriology Laboratory Branch (MLB) will be held in August 2009 with Dr. Fleenor 
chairing the review panel.  Provisional interferon gamma release assay (IGRA) guidelines were 
presented during the European Respiratory Society conference. 
 
The DTBE web page was updated to be consistent with the formats of other CDC web pages.  
DTBE welcomes feedback and suggestions from ACET to improve the revised TB web page.  
The 9th Annual TB Education and Training Network and the 1st TB Program Evaluation Network 
Conference will be jointly held on July 28-30, 2009.  The application review process for the TB 
Trials Consortium (TBTC) re-competition is underway. 
 
DTBE supported CDC’s H1N1 influenza response and will complete its TB-specific pandemic 
influenza operational plan by July 28, 2009.  The Food and Drug Administration (FDA) Anti-
Infective Advisory Committee held a meeting in June 2009 to discuss using FDA’s regulatory 
authority to accelerate approval of promising new agents for treatment of multidrug-resistant TB 
(MDR-TB).  The committee agreed to use sputum conversion within a period of three to six 
months as a surrogate marker of efficacy.  DTBE will represent CDC during the Federal TB 
Task Force (FTBTF) meeting on August 26, 2009. 
 
DTBE will target $3 million in new funding to prevent future TB cases and implement elements 
of the Extensively Drug-Resistant TB (XDR-TB) Plan that was published in 2009 in the Morbidity 
and Mortality Weekly Report (MMWR).  Cure TB is scheduled to be the first of the DTBE-funded 
U.S.-Mexico binational projects that will be evaluated in August-September 2009.  The National 
TB Indicators Project was launched in March 2009. 
 
Dr. Castro provided additional details on DTBE’s activities and future plans in response to 
ACET’s specific questions and comments.  DTBE intends to schedule a briefing with Dr. Frieden 
in the near future.  The STOP TB Elimination Plan will be one of the key topics DTBE will 
discuss with Dr. Frieden. 
 
Dr. Castro clarified that he welcomes the opportunity for DTBE staff to continue to participate in 
on-the-ground investigations, surveillance and other aspects of CDC’s response to H1N1 
influenza.  However, he will not allow TB control efforts to cease while DTBE staff is involved in 
the H1N1 influenza response.  In the event H1N1 influenza becomes more severe and causes 
significant mortality in the future, DTBE will retain its core functions of TB surveillance, 
laboratory support to diagnose TB cases, communications and contact investigations. 
 
Dr. Castro raised the possibility of ACET formalizing a resolution regarding the need for TB 
programs to contribute to the H1N1 influenza response, while providing continuity for TB case 
management.  During the June 2009 National Tuberculosis Controllers Association (NTCA) 
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meeting, he proposed administering seasonal influenza vaccine in TB clinics because many 
patients only receive care in these settings. 
In response to Dr. Castro’s request, Dr. Fleenor confirmed that he would identify a few ACET 
members to utilize their TB expertise to provide guidance to the CDC National Institute for 
Occupational Safety and Health during upcoming meetings on the appropriateness of 
respiratory protection for airborne transmission of H1N1 influenza with weak scientific evidence. 
 
Several ACET members described actions that were taken to maintain TB control at state and 
local levels during the H1N1 influenza outbreak.  The members also made two key suggestions 
for DTBE to consider in its future activities.  In addition to scheduling a briefing with Dr. Frieden, 
DTBE also should meet with Mr. Salinas due to his long history as a TB public health advisor 
and extensive experience in TB control.  DTBE should use the new Administration and the 
H1N1 influenza outbreak as opportunities to revisit the possibility of leveraging bioterrorism 
funds for TB. 
 
 
 
 
 
Dr. Drew Posey, of the DGMQ Immigrant, Refugee and Migrant Health Branch, reported on 
DGMQ’s ongoing activities related to the TB Technical Instructions (TBTIs), Electronic Disease 
Notification (EDN) system, and HIV Notice of Proposed Rule Making (NPRM).  In terms of the 
TBTIs, all immigrants and refugees who apply for U.S. immigration are required to undergo TB 
screening.  The 1991 TBTIs only relied on sputum smears, but the 2007 TBTIs require cultures, 
drug susceptibility testing (DST) on positive isolates, and directly observed therapy (DOT) for 
persons with TB in accordance with U.S. guidelines. 
 
Since 2007, DGMQ has implemented the TBTIs in 24 countries.  At this time, 45% of U.S.-
bound immigrants and >50% of U.S.-bound refugees are screened with the new TBTIs.  DGMQ 
is particularly pleased that China recently began implementing the TBTIs because this high-
burden country is the third largest source of U.S-bound immigrants.  Other new countries where 
the TBTIs are being implemented include Ethiopia, Japan, Jordan, Kenya and Taiwan. 
 
Efforts are underway to implement the TBTIs in Chad, Ghana, Guatemala, India and Nigeria.  
DGMQ hopes to conduct a site visit in Russia in the summer of 2010 to explore the possibility of 
implementation in this country.  ACET and NTCA will conduct an evaluation of the International 
Organization for Migration (IOM) program the week of August 10, 2009 in Nepal.  This country is 
the site of the Bhutanese refugee resettlement and will account for >15,000 arrivals in FY2009. 
 
Based on data collected in the first year the TBTIs were implemented in the Philippines and 
Vietnam, the addition of cultures yielded two to three times more applicants with TB.  In both 
countries, ~1% of applicants were culture-positive.  In terms of the resistance patterns of 
culture-positive applicants, 71% of 289 persons had pansusceptible TB in the Philippines and 
47% of 86 persons had pansusceptible TB in Vietnam; 3% of 12 persons had MDR-TB in the 
Philippines and 5% of 10 persons had MDR-TB in Vietnam. 
 
Update by the Division of Global Migration and Quarantine (DGMQ) 
ACET Meeting Minutes                                   July 14-15, 2009                                                        Page 6 
 
 
  
In terms of treatment outcomes of pulmonary TB cases, most applicants in both countries were 
undergoing treatment, completed treatment or were cured.  In the Philippines, 14% of 73 
applicants did not register for treatment at the panel physician site, while only 3% of five 
applicants did not register in Vietnam.  The ACET/NTCA evaluation team made a critically 
important recommendation for CDC to add a second DOT site in the Philippines to increase the 
number of applicants with pulmonary TB who register for treatment.  CDC added another DOT 
site at Perpetual Succour Hospital in the Philippines earlier in 2009.  CDC’s formal response to 
the evaluation team’s recommendations for the Philippines TB program was distributed to ACET 
for review. 
 
U.S. Department of State (DOS) forms are completed by overseas panel physicians and are 
being updated to incorporate changes in the 2007 TBTIs.  Implementation of the updated DOS 
forms is targeted for October 1, 2009 in parallel to updates of the EDN system and the EDN-
IOM electronic interface for refugee medical examinations. 
 
The TBTI document is being updated to be consistent with the new DOS forms and allow for 
incorporation of changes based on recommendations made by the TBTI Workgroup and the 
evaluation team for the implementation of the TBTIs in the Philippines.  Implementation of the 
updated TBTI document and the new DOS forms will be linked.  The final draft of the updated 
document was reviewed by the TBTI Workgroup and is currently undergoing the CDC clearance 
process. 
 
In terms of EDN, this electronic system allows information to be sent to receiving health 
departments on all refugees who arrive in the United States and all immigrants who arrive in the 
United States with a Class A or Class B TB condition.  EDN also serves as a mechanism for 
health departments to enter results of post-arrival TB evaluations.  DGMQ consolidated its EDN 
leadership with a medical director, program manager, data center manager and informatics 
project manager to address current problems in the system, particularly the significant eight-
week backlog of ~15,000 records. 
 
DGMQ is taking a number of actions to resolve the EDN backlog.  Additional data entry staff will 
be hired to increase the number of personnel from 10 to 20.  A night shift will be included within 
the next two to four weeks.  An interim plan was proposed to be in effect until September 30, 
2009.  Records received electronically would be transmitted to states with or without scanning to 
reduce the burden on data entry staff and facilitate faster processing of records.  EDN resources 
would be concentrated on new arrivals.  EDN users have a deadline to submit comments on the 
proposed interim plan by July 20, 2009. 
 
In terms of the HIV entry ban, the NPRM was published in the Federal Register on July 2, 2009 
and proposed removing HIV from the list of inadmissible conditions.  If the NPRM goes into 
effect, testing for HIV would no longer be required by panel physicians and civil surgeons and 
applicants with HIV infection would no longer require a waiver for entry into the United States.  
However, the waiver requirement would not apply to refugees.  The rationale for the NPRM is 
three-fold.  The risk to the public’s health is not threatened by the entry of HIV-infected 
immigrants and refugees.  The risk posed by HIV-infected persons is not based on nationality.  
HIV is not a new disease in the United States and accounts for >1 million cases in the country. 
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The 45-day public comment period for the NPRM will end in August 2009.  CDC is obligated to 
review and respond to all public comments and has received >16,000 comments to date that 
primarily have been favorable.  The regulations would become effective only after a Final Rule 
is issued.  However, the Final Rule would not prohibit a standard of care for TB patients to be 
tested for HIV.  CDC anticipates that the regulations would not become effective before October 
1, 2009. 
 
DGMQ is currently informing ACET, NTCA, the Association of Refugee Health Coordinators and 
other key non-U.S. government groups about the NPRM.  DGMQ will develop guidance for 
panel physicians, civil surgeons and domestic refugee health programs if the proposed HIV 
regulations become effective. 
 
On the one hand, some ACET members were pleased with the NPRM because the proposed 
HIV regulations would reduce the stigma and discrimination associated with HIV-positive 
immigrants and refugees.  On the other hand, some ACET members expressed concern about 
the tremendous burden that would be placed on the public health system at state and local 
levels to resettle HIV-positive refugees in the United States with employment and health care. 
 
ACET advised DGMQ to attempt to leverage resources to expand the TBTIs to include non-
immigrant visa applicants, such as students and workers with H or L visas, as well as individuals 
who enter the United States under the Compact of Federal Free Association.  These groups are 
not required to be screened for TB prior to U.S. entry. 
 
Dr. Castro raised the possibility of ACET formalizing a resolution for CDC to strengthen local TB 
control programs overseas in all activities that are conducted overseas to improve screening 
procedures to reduce the importation of TB into the United States. 
 
 
 
 
 
Dr. John Oeltmann, of DTBE, presented a study CDC conducted to report the prevalence of 
substance abuse among TB cases reported in the United Sates and examine the relationship 
between substance abuse and TB transmission.  An overlooked and rather large tide pool of 
disease is among persons who abuse substances.  For example, substance abuse is the third 
most significant risk factor for TB. 
 
CDC’s investigations from 2005-2008 showed that 10 of 13 TB outbreaks had populations with 
at least 50% of substance abusers.  The risk for TB remains higher among certain demographic 
groups, including those who abuse substances.  The ability of substance abuse to hinder TB 
control efforts is well documented in the literature, but no national summary has been developed 
to date to demonstrate the impact of substance abuse on TB control. 
 
For purposes of the study, CDC defined “substance abuse” as self-reported excessive alcohol 
use or injection or non-injection use of illicit drugs during the year prior to TB diagnosis.  All 
Overview of TB and Substance Abuse in the United States 
 
 
ACET Meeting Minutes                                   July 14-15, 2009                                                        Page 8 
  
incident TB cases >15 years of age reported to the National TB Surveillance System from 1997-
2006 were included in the study.  Prevalence was calculated based on injection drug use, non-
injection drug use or excess alcohol use.  A “substance abuse” composite variable was 
developed for any of these substances.  Genotyping data were compiled from 2004-2005 to 
assess the relationship between substance abuse and county-level genotype clustering. 
To evaluate a potential association with TB and increased transmission, CDC asked research 
questions to determine whether substance abuse was related to positive sputum-smear results 
at diagnosis, treatment failure or involvement in a county-level genotype cluster.  The study was 
controlled for a number of confounders, including gender, HIV status, race, place of birth, 
homelessness and incarceration in a correctional facility.  Due to the large sample size, a small 
p-value <0.01 was selected. 
 
Key results of the study are highlighted as follows.  In the study period of 1997-2006, 153,268 
TB cases met the inclusion criteria.  The prevalence of substance abuse was 19% among all 
cases and 29% of U.S.-born cases; 35.3% among U.S-born males and 16.9% among U.S.-born 
females; and 12.9% among foreign-born males and 1.5% among foreign-born females.  Excess 
alcohol use was the most frequently reported substance in 23% of U.S.-born cases and 7% of 
foreign-born cases.  Substance abuse was a more prevalent risk factor for TB than recent 
immigration, congregate settings, homelessness, HIV infection and high-risk occupation when 
U.S.-born and foreign-born cases were combined, but the burden was significantly higher in 
U.S.-born cases alone. 
 
Of 105,688 cases, the odds ratios of an association between substance abuse and positive 
sputum-smear results at diagnosis were 1.2 for HIV-positive cases, 1.8 for HIV-negative cases, 
and 1.6 for cases with an unknown HIV status.  Of 100,775 cases, the odds ratios of an 
association between substance abuse and treatment failure were 2.4 for females and 1.5 for 
males.  Of 11,874 cases, the odds ratios of an association between substance abuse and 
involvement in a county-level genotype cluster were 2.3 for U.S.-born cases and 1.5 for foreign-
born cases. 
 
CDC reached a number of conclusions based on the study results.  Of the entire study 
population, 1 in 5 patients reported substance abuse and 1 in 3 U.S.-born patients reported 
substance abuse.  The prevalence of substance abuse in TB cases was greater than other 
established risk factors, such as recent immigration to the United States, residence in a 
congregate setting, homelessness, HIV infection or high-risk occupation.  Patients who abuse 
substances were more likely to have sputum smear-positive disease, fail treatment and be 
involved in a genotype cluster representing recent TB transmission.  Overall, the study showed 
that substance abuse was common and fueled TB transmission. 
 
Potential explanations for the impact of substance abuse on TB include extended exposure to 
TB in drug use venues or other poorly ventilated and crowded settings, compromised immune 
systems of substance abusers, less access to routine care among substance abusers, and 
routine TB control measures that are ineffective for substance abusers.  Substance abuse is 
related to four major barriers to TB control in the United States. 
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Substance abuse is associated with sputum smear-positive disease that delays care and 
prolongs infectiousness.  Substance abusers often are unwilling or unable to recall the names of 
contacts.  Contacts of patients with TB disease who abuse substances are more difficult to 
locate and less likely to be screened for TB disease and latent TB infection (LTBI).  Contacts 
who abuse substances are less likely to initiate, adhere to and complete treatment.  The 
NCHHSTP Drug Use Workgroup drafted guidelines for integrating HIV, hepatitis, STD and TB  
 
 
services for persons using illicit drugs.  The guidelines are based on a study that was published 
in the Archives of Internal Medicine in January 2009. 
 
ACET thanked Dr. Oeltmann for presenting CDC’s comprehensive study because many 
members have expressed a strong interest in addressing substance abuse in TB patients for 
quite some time.  A number of ACET members made suggestions for the NCHHSTP Drug Use 
Workgroup to consider in its ongoing efforts to finalize the integrated guidelines for persons 
using illicit drugs. 
 
• Caution should be taken against over-generalizing or making broad statements on 
substance abuse.  For example, CDC’s study does not clearly distinguish between 
“alcohol abuse” and “alcoholism” and also does not describe behaviors or various 
sociodemographic factors to define the “dependent” substance abuse population.  The 
NCHHSTP Drug Use Workgroup should consider these issues while revising the draft 
guidelines. 
• Best practices, lessons learned and field experiences should be compiled from San 
Francisco and other TB programs throughout the country that have taken advantage of 
the lengthy treatment period for TB to also treat substance abuse in their patient 
populations.  These techniques should be rigorously evaluated to inform the 
development and implementation of CDC’s guidelines. 
• The NCHHSTP Drug Use Workgroup should obtain input from the ACET African 
American (AA) Workgroup in finalizing the guidelines because AAs had the highest 
prevalence of substance abuse than any other racial/ethnic group of TB patients in the 
CDC study. 
• The drug use guidelines should include specific recommendations for “middle class” 
substance abusers as well as those with a high socioeconomic status. 
• CDC should review non-traditional models of multidisciplinary clinics that include clinical 
care, psychiatry, substance abuse and a knowledgeable intermediary who would be 
available to interact with patients. 
 
Dr. Castro followed-up on one of ACET’s suggestions by proposing that CDC engage in an 
interagency effort with federal partners to collectively address confounding problems in TB 
patients.  For example, CDC’s partnership should include the Substance Abuse and Mental 
Health Services Administration (SAMHSA) for TB patients who need rehabilitation services, 
Health Resources and Services Administration (HRSA) for TB patients who are homeless, and 
correctional health agencies for TB patients who will be released from correctional facilities. 
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 Dr. Castro further explained that CDC-funded TB programs could make referrals to SAMHSA-
funded rehabilitation centers or HRSA-funded homeless centers for TB patients who need these 
services.  He also noted that the effectiveness of administering DOT in methadone clinics was 
well documented in the literature during the resurgence of TB. 
 
 
 
 
 
 
 
 
Dr. Thomas Navin, of DTBE, reported that CDC’s TB Genotyping Information Management 
System (TB-GIMS) is a single web location where isolate submission is requested, genotyping 
results are posted and analysis occurs.  With the exception of paperwork to submit isolates, TB 
control staff will not be required to enter any additional data.  Genotyping and surveillance data 
will be automatically updated and placed in a single web location.  Beta testing of TB GIMS is 
underway and the final version of the system will be released in January 2010 in parallel to the 
transition of CDC’s surveillance data set to real-time data. 
 
CDC’s aberration detection developmental activities include risk factor summaries, measures of 
space and time aberrations, aberration detection alerts and revised epidemiologic curve 
representations.  Maps will be produced at national, state and county levels to detect clusters of 
TB genotypes.  Log-likelihood ratios (LLRs) also will be developed to measure the difference 
between the observed and expected geospatial concentration.  LLRs are weighted by case 
count and also are log transformed.  LLRs are widely studied in statistical analyses and used by 
the SaTScan system. 
 
LLRs in recent TB outbreaks CDC investigated throughout the country were quite high and 
ranged from 7-33.6.  CDC also evaluated the 14 highest LLR clusters ranging from 20-59 that 
represented significant problems for TB controllers.  Based on previous evaluations by experts, 
the threshold for LLRs of concern is ~6.  High LLRs can be used to identify clusters of major 
public health importance. 
 
LLRs are effective in determining whether a cluster has become or has been a problem, but are 
ineffective in determining whether a cluster still is a problem.  CDC has developed two 
approaches to determine if a cluster still is a problem.  First, cumulative six-month LLR is used 
to measure LLRs in successive six-month time windows.  Second, cumulative sum analysis is 
performed to examine the time between cases to detect when cases occur more frequently than 
expected.  CDC will use cumulative LLRs, current six-month LLRs and risk factors to send alerts 
of the current overall status of TB outbreak aberrations to TB controllers. 
 
The TB Epidemiologic Studies Consortium (TBESC) is funding Task Order 26 to evaluate the 
sensitivity and specificity of LLRs in detecting outbreaks at lower cutoff values.  The study is 
being conducted in Georgia, Maryland, Massachusetts and Texas.  CDC’s next steps in its 
activities to detect TB outbreak aberrations include the development of phase 2 of TB GIMS with 
Update on Detection of TB Outbreak Aberrations 
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 more interactive maps and additional functions.  Surge capacity to respond to outbreaks was 
increased with the addition of Drs. Juliana Grant and Adam Langer to the DTBE Outbreak 
Investigations Team. 
 
Task Order 26 will be conducted over the next two years and will produce the most solid data set 
to date on distinguishing between clusters of public health significance and non-significant 
clusters.  CDC will use data from Task Order 26 to refine the current alert system.  CDC will offer 
training on contact, cluster and outbreak investigation modules.  Mycobacterial interspersed 
repetitive unit (MIRU) 2 typing of isolates will increase discrimination in detecting clusters of 
importance. 
Dr. Navin concluded his update by asking an ACET member to participate on DTBE’s Advisory 
Group to assist in developing consensus-based data sharing guidelines, policies and 
safeguards for use by TB controllers.  He also requested ACET’s input on whether patient 
confidentiality could still be protected if state data on TB outbreak aberrations were publicly 
shared more broadly at the national level.  States could then endorse or opt-out of the data 
sharing guidelines. 
 
ACET made a number of comments and suggestions in response to Dr. Navin’s request for 
input. 
 
• CDC should ensure that the TB aberration detection alert system is beneficial to users of 
the system in actually detecting aberrations earlier. 
• CDC should structure the data sharing agreements to make TB outbreak aberration data 
available to local and county health departments. 
• CDC’s RVCT training should offer clear guidance to HCP on incorporating zip codes into 
the TB aberration detection alert system for TB patients who are homeless.  For 
example, zip codes of homeless shelters or clinics where homeless TB patients received 
treatment could be entered into the system.  This approach would provide TB controllers 
with better capacity to group homeless persons in a potential outbreak. 
• CDC should ensure that its existing data sharing guidelines for states to share data on 
reportable diseases are consistent with the new data sharing guidelines for TB 
controllers. 
• CDC should closely monitor any adverse impacts of reductions in state laboratory staff 
on monthly shipments of cultures to state laboratories for genotyping. 
 
Dr. Navin provided additional details in response to ACET’s comments and suggestions.  Each 
state will designate an administrator to make decisions on individuals who can have access to 
TB outbreak aberration data.  County health departments will have access to line-listed data, 
but will not have rights to edit surveillance data.  CDC created a FedEx account for health 
departments to easily and rapidly ship cultures to laboratories for genotyping.  The Michigan 
laboratory is returning 90% of genotyping results to health departments within two weeks. 
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Dr. Randall Reves, of the Denver Public Health Department, provided an update on the TEP on 
behalf of STOP TB USA.  The TB control community failed to meet the TB elimination goals.  
ACET’s 1989 goal to eliminate TB by 2010 based on a definition of 1 case/1 million population 
will not be achieved.  The Institute of Medicine’s (IoM) 2000 goal to eliminate TB by 2035 with 
the development and implementation of new prevention tools and the expansion of LTBI 
treatment is unlikely.  Based on a 3.8% reduction in TB cases per year since 2003, CDC has 
projected that TB elimination could be achieved in 2104 in the general U.S. population.  
Because non-Hispanic whites account for only 17% of TB cases in the United States at this 
time, CDC’s projections also show that minorities would exclusively account for all TB cases in 
50 years. 
 
Mr. Van Simsiman is a member of the Filipino community who attended a recent community 
consultation on TB.  He commented that TB elimination in 100 years would be meaningless to 
him.  He emphasized that establishing progressive interim goals at ten-year periods would be 
more operationally realistic.  During the consultation, Mr. Simsiman asked about actions that 
need to be taken to ensure funding and support for TB elimination efforts continue.  He also 
inquired about the persons and entities that would be held accountable for measuring progress 
in performance and ultimate achievement of the TEP goals. 
 
The TEP Writing Committee does not believe a new plan is needed because the key guidance 
remains valid.  However, the IoM’s recommendations to meet all of the TEP goals have not 
been implemented to date.  The IoM goals of maintaining TB control despite the decline in the 
number of cases and increasing U.S. involvement in global TB control have been achieved 
based on a continual decline in TB cases since 1993 and increased funding for TB. 
 
The IoM goal of accelerating the decline in the number of TB cases by increasing targeted 
testing and treatment of LTBI has not been achieved because LTBI treatment is limited to public 
health departments, a few prisons and refugee clinics.  Private practitioners who are treating 
patients with risk factors for TB are not identifying, testing and providing treatment to these 
patients.  CDC data showed increasing prevalence in LTBI among the foreign-born population 
(FBP) in 1999-2000. 
 
The IoM goals of developing new diagnostics, treatment and prevention tools as well as 
mobilizing and sustaining public support have not been fully achieved.  Research in these areas 
was expanded, but implementation of new tools has been limited at federal, state and local 
levels.  Moreover, success in mobilizing support has been modest at best. 
 
On an individual level, the TB control community failed a woman 19 years of age from Nepal 
who attended school in Colorado and died from TB.  Stigma and perceptions regarding TB from 
different parts of the world inhibit solid actions on TB elimination.  TB prevention is an essential 
component of TB elimination, but has become less of a priority.  Due to resource constraints in 
state and local TB programs, efforts are limited to treating TB cases and conducting contact 
investigations. 
Update on the U.S. TB Elimination Plan (TEP) 
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The TB control community recognizes the critical need to take more aggressive actions in TB 
elimination.  TB case detection and curative treatment are still necessary, but mobilization for 
TB prevention and elimination is essential.  Outrage over the growing health disparity in which 
TB will be an exclusive disease among minorities in 50 years should be shared with 
communities.  Time is being wasted on learning to use poor second-line drugs.  Communities 
should be reminded that local and state TB programs are the only mechanisms to stop the 
development and spread of XDR-TB in the United States.  The benefits of TB elimination by 
2035 also should be widely publicized to communities, such as 253,000 fewer active TB cases, 
15,200 fewer TB-associated deaths, and ~$1.3 billion in cost-savings from TB treatment. 
 
The TEP Writing Committee completed the first draft of the plan in October 2008 with funding 
and support from NTCA and the American Thoracic Society (ATS) for conference calls, writer/ 
editor expertise and graphics.  The draft plan was revised based on external input from DTBE, 
the Department of Homeland Security, state and local health departments, and academic 
institutions.  The Executive Summary of the TEP was posted on the NTCA website in June 2009 
for a 30-day open comment period.  The next steps in the TEP will be to develop advocacy 
documents, create communication tools to engage community members, and post other 
sections on the website, particularly the U.S.-born, foreign-born and low incidence chapters. 
 
Dr. Reves concluded his update by asking ACET to provide him with comments on the TEP 
Executive Summary at rreves@dhha.org.  He also requested ACET’s review and formal 
endorsement after the entire TEP is updated as well as recommendations on ensuring the plan 
is implemented. 
 
ACET commended STOP TB USA and the TEP Writing Committee for updating the plan with a 
voluntary and grassroots effort.  Several ACET members made suggestions for the Writing 
Committee to consider in broadly disseminating and implementing the TEP. 
 
• Successful models in reaching specific populations for other diseases should be used to 
ensure implementation of the TEP.  For example, churches, beauty salons and barber 
shops served as extremely effective partners with CDC to reach the AA community 
regarding breast and prostate cancers. 
• The National Medical Association (NMA) should be used to educate and engage AA 
physicians in the TEP.  For example, an NMA member could serve as a reviewer of the 
TEP. 
• The Writing Committee should incorporate recommendations into the TEP from CDC’s 
previous consultations on TB in the AA community. 
• CDC should take more aggressive actions in holding grantees accountable for targeting 
federal cooperative agreement funds to AAs and other minority groups that are 
disproportionately impacted by TB in the United States. 
• The TEP should be provided to HRSA-funded Clinicians Networks and Community 
Health Centers for wider distribution during conferences of these grantees.  Providers in 
these HRSA-funded settings serve homeless persons, HIV-positive persons, migrants 
and other populations that are at risk for TB. 
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Dr. Castro made additional suggestions to increase awareness and dissemination of the TEP.  
First, the TEP and supporting data should be directly distributed to influential leaders in the AA 
and Hispanic communities, such as elected officials and the Congressional Black and Hispanic 
Caucuses.  Second, the TEP should be linked to the Comprehensive TB Elimination Act that 
authorizes TB elimination activities at the federal level.  However, a footnote should be added to 
the TEP to emphasize that despite this federal law, no funding has been appropriated to date for 
TB elimination.  Third, a charter for TB patients or affected communities should be developed to 
accompany the TEP and document endorsement of the plan by the target audience. 
 
Ms. Fran DuMelle, of ATS, is the ACET liaison to STOP TB USA.  She announced that tools will 
be designed and lessons learned from previous implementation plans will be applied to enhance 
advocacy for and funding of the TEP at state and national levels.  She asked ACET to provide 
input on additional tools that should be created for implementation of the TEP. 
 
On behalf of STOP TB USA, Ms. DuMelle, presented a plaque to Dr. Reves in recognition of his 
dedication and commitment to updating the TEP and overseeing this grassroots initiative.  The 
participants joined Ms. DuMelle in applauding Dr. Reves for his outstanding efforts. 
 
Dr. Fleenor closed the discussion by confirming that the TEP would be placed on the agenda for 
the October 2009 meeting for ACET’s review and possible adoption of a formal resolution.  To 
ensure compliance with the charter, however, he clarified that any recommendations ACET 
passed on the TEP would be directed to the Director of CDC and Secretary of HHS. 
 
 
 
 
 
Ms. Kai Young, of DTBE, explained that DTBE formed the TB Program Evaluation Workgroup 
because the use of data for program improvement was limited prior to 2000.  The workgroup’s 
efforts led to the development of NTIP to facilitate a collaborative impact evaluation and 
enhance CDC’s effectiveness in TB elimination.  NTIP is a user-friendly program monitoring 
system that strengthens collaboration, increases the use of existing data, helps prioritize efforts 
for program evaluation, and facilitates the integration of monitoring and evaluation into routine 
program practice. 
 
DTBE developed NTIP based on the steps in CDC’s framework for program evaluation, such as 
engaging stakeholders, describing the program, focusing the evaluation design, gathering 
credible evidence, justifying conclusions, and using and sharing lessons learned.  Standards in 
CDC’s framework of utility, feasibility, propriety and accuracy also guided the design of NTIP.  
The workgroup identified 15 categories of high-priority objectives for TB programs and 
established national TB program objectives and performance targets for 2015.  NTIP generates 
indicator reports that monitor progress toward achieving these national objectives, focus 
program evaluation efforts, and provide performance targets as benchmarks for assessment.   
 
DTBE created standardized indicator measurements for NTIP by engaging stakeholders at state 
and local levels in an iterative process through a series of conference calls.  An intensive review 
Update on the National Tuberculosis Indicators Project (NTIP) 
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 of NTIP also was conducted with a larger group of external partners.  NTIP indicator reports 
were designed based on DTBE’s national TB program objectives and templates from the 
California TB Indicators Project.  Each NTIP report contains a graph to illustrate state 
performance in a national objective, a table with state data, and a methods summary 
highlighting the national objective, indicator, cohort, data sources and calculations.  States can 
use the NTIP reports to compare their performance with national results and targets. 
DTBE will gather data from the CDC National TB Surveillance System to develop and distribute 
NTIP reports to all grantees for assistance in preparing progress reports.  NTIP reports will have 
the ability to facilitate discussion, educate staff and encourage problem solving between DTBE 
and program areas, program managers and staff, and programs and community partners.  NTIP 
reports also will play a role in tracking program progress, enhancing capacity to provide 
guidance and technical assistance, and strengthening collaboration to detect and understand 
barriers and improve program effectiveness. 
 
DTBE created a process to integrate NTIP into program practice.  For programs that meet NTIP 
targets, an evaluation will be performed to identify and widely share best practices.  For 
programs that do not meet NTIP targets, an evaluation plan will be developed to better 
understand barriers and challenges.  Updates on progress in the evaluation will be periodically 
submitted to DTBE.  Upon completion of the evaluation, the program will refine current activities 
or develop new initiatives based on the findings and then implement improvements.  Because 
state programs provide leadership and technical assistance to local jurisdictions in the 
evaluation process, NTIP reports will be distributed to regional and county levels. 
 
DTBE launched NTIP in March 2009 for programs to pilot the system in reporting their 2008 
progress.  Programs are currently using NTIP to prepare applications for the 2010-2015 TB 
cooperative agreements.  Programs will be required to report progress using NTIP beginning in 
2010.  County-level reports will be available to support collaborations between state and local 
programs.  NTIP will capture real-time reporting and line-listed data.  DTBE hopes NTIP will 
encourage programs to submit data more often to CDC. 
 
Overall, NTIP will reinforce national TB priorities at state and local levels.  Existing data will be 
used to measure progress and impact.  Priorities will be identified for program improvement, 
reporting and technical assistance.  NTIP also will facilitate evidence-based practice and 
enhance collaboration between DTBE staff and among partners at all levels.  Ms. Young 
concluded her update by presenting a live demonstration of NTIP. 
 
ACET made two key suggestions for DTBE to consider in the national implementation of NTIP 
in 2010.  First, DTBE should explore the possibility of incorporating language into the TB 
cooperative agreements to require grantees to submit data to CDC on a timelier basis.  This 
requirement would help DTBE to generate NTIP reports on a quarterly basis.  Second, DTBE 
should issue clear guidance to grantees on using NTIP to submit interim progress reports to 
CDC. 
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Model TB Prevention and Control Act Workgroup.  Ms. Melisa Thombley, of DTBE, reported 
on the status of five major activities CDC conducted to build on ACET’s 1993 recommendations 
regarding TB laws. 
 
In activity 1, CDC commissioned the Centers for Law and the Public’s Health (CLPH) to review, 
organize and characterize legislative regulatory or judicial case laws for TB control in 25 
selected states and jurisdictions that expressly relate to the control of TB or MDR-/XDR-TB 
cases through state or local health departments, other governmental actors and private sector 
partners.  This activity focused on express TB control laws and excluded general communicable 
disease laws.  The Express Tuberculosis Control Laws in Selected U.S. Jurisdictions Report 
was posted on the CLPH website in October 2008 and will be available on the CDC and NTCA 
websites in the near future. 
 
In activity 2, CDC developed a scenario tool to assess jurisdiction-specific understanding and 
sufficiency of TB control laws.  Officials from relevant sectors were convened to implement the 
scenario tool and identify potential gaps in legal authorities that might inform the development of 
the TB control model act.  The scenario tool was piloted in Florida and Kansas in May 2008 and 
would be made available to other jurisdictions following implementation of the pilot. 
 
CDC also created companion implementation guidelines for any jurisdiction that expected to use 
the scenario tool.  In response to ACET’s previous recommendation for jurisdictions to use the 
scenario-based assessment tool before implementing any of the options for the model TB 
control act, this resource will be disseminated to TB control officials in collaboration with ACET 
and NTCA.  The tool will be posted on the websites of CDC, NTCA and other groups over the 
next few months. 
 
In activity 3, CDC identified, reviewed and characterized TB control laws in selected tribes to 
inform the development of the TB control model act.  Data sources that guided this activity 
included the National Tribal Justice Resource Center, Tribal Court Clearinghouse of the Tribal 
Law and Policy Institute, and HHS Office of the General Counsel in Region IX.  CDC is currently 
consulting with the Indian Health Service Office of the General Counsel to identify potential 
concerns with posting the report on websites because tribal legal counsel did not review the 
document.  In the event the report cannot be publicly available on websites, CDC will 
disseminate the report to tribal counterparts for review and feedback. 
 
In activity 4, CDC developed a handbook and companion instructional slide unit on TB control 
laws that local, state and tribal public health practitioners and their legal counsel can use to 
improve their understanding of and competency in applying TB control laws.  These resources 
are targeted to public health practitioners who are active in TB control at local, state and tribal 
levels and their legal counsel. 
 
The materials focus on relevant local, state, tribal, federal and international laws.  Tuberculosis 
Control Laws and Policies: A Handbook for Public Health and Legal Practitioners and the 
ACET Workgroup Reports 
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companion instructional slide unit are currently in the final phase of the CDC clearance process 
and should be available online over the next few weeks.  CDC will solicit input from ACET and 
NTCA on additional options to disseminate these resources. 
 
In activity 5, CDC commissioned CLPH to develop a state “model act” on TB control to provide 
state and local public health officials, policymakers, legislators and others with a tool to review 
and potentially strengthen their respective TB prevention and control laws.  After the first draft of 
the model act was developed and revised based on comments from CDC and key partners, 
CLPH informed CDC of its inability to be totally responsive to comments on the second draft in 
June 2009. 
 
CLPH used its Turning Point Act to draft the TB control model act, but CDC and key partners 
found the broad language and numerous Constitutional provisions to be problematic for a TB 
control law.  Moreover, CLPH’s Turning Point Act was offensive to many workgroup members 
because its overall tone suggested that public health officials routinely violate the Constitutional 
rights of patients.  Several workgroup members representing ACET, NTCA and other groups 
informed CDC that their respective organizations would not endorse the TB control model act 
CLPH had written.  CDC is currently consulting with its Office of General Counsel to formulate a 
disclaimer in the event CLPH decides to disseminate the TB control model act. 
 
To resolve this problem, CDC will collaborate with ACET, NTCA and other key partners to 
develop a menu of options for state TB control laws to better address the diverse needs of 
states.  The menu will be modeled after the methodology that was used to create CDC’s “Menu 
of Suggested Provisions for Public Health Mutual Aid Agreements” and also will be based on 
existing best practices for state control laws. 
 
State TB control laws will be categorized using ACET’s 1993 recommendations that were 
published in the MMWR.  General communicable disease control provisions will be included in 
the menu where appropriate.  CDC will convene an in-person meeting with state TB controllers 
and legal counsel for state and local health departments to facilitate the development of the 
menu. 
 
Dr. Fleenor confirmed that in response to Ms. Thombley’s request, the menu of options for TB 
control laws would be placed on future meeting agendas for ACET to provide input to CDC on 
an ongoing basis during the development of this activity. 
 
IGRA Workgroup.  Dr. Iram Bakhtawar is a member of both ACET and the workgroup.  She 
presented the report on behalf of Dr. Masahiro Narita, chair of the workgroup, who was unable 
to attend the ACET meeting.  CDC convened an expert panel in August 2008 to update its 2005 
IGRA guidelines to reflect more recent data.  The workgroup reviewed the initial draft and 
provided comments to the authors on specific areas in the IGRA guidelines that needed 
clarification.  The revised draft was presented during the June 2009 NTCA meeting for the 
authors to obtain additional input. 
 
Dr. Bakhtawar concluded that the workgroup is now asking ACET to adopt a formal resolution 
for CDC to publish useful IGRA guidelines as soon as possible.  In preparation of ACET taking 
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formal action on the IGRA guidelines during the business session on the following day, Dr. 
Fleenor confirmed that the most recent draft would be distributed to ACET for review before the 
meeting was recessed. 
 
Foreign-Born Workgroup.  Dr. Dolly Katz, of DTBE, reported that the workgroup was formed 
to update CDC’s 1998 guidelines on TB control in FBP to reflect more recent changes in the 
epidemiology of TB in FBP and new tests for LTBI.  The workgroup is currently revising the draft 
guidelines and will convene an in-person meeting with ACET members, TB controllers and CDC 
staff on July 27, 2009 to reach consensus on three major areas of the guidelines that have not 
been resolved to date. 
 
The first unresolved issue is “who should be screened.”  The current guidance is intended for 
the management of FBP who present to any type of healthcare provider for services of any kind.  
The workgroup has proposed a recommendation to screen all FBP for LTBI at least once except 
those from low-risk countries.  During the meeting, the workgroup will attempt to reach 
consensus on whether the guidelines should reflect the best approach to the prevention of TB in 
FBP irrespective of individual capacity or if capacity should be taken into account. 
 
The second unresolved issue is “what screening method” should be used (i.e., IGRA versus 
tuberculin skin test (TST)).  During the meeting, the workgroup will attempt to reach consensus 
on whether the guidelines should be permissive or specifically advocate for the use of IGRA in 
FBP. 
 
The third unresolved issue is “who should be treated.”  A decision to test will no longer serve as 
a decision to treat.  The workgroup has proposed a recommendation to base the decision to 
treat on the risk of progression to active TB.  High-risk FBP would be treated as well, such as 
recent arrivals from foreign countries, younger persons and individuals with HIV or diabetes. 
 
During the meeting, the workgroup will attempt to reach consensus on the extent to which the 
guidelines should be prescriptive, such as establishing an age cutoff for treatment, describing 
each foreign-born subgroup that should and should not be treated, or offering general guidance 
to provide physicians with flexibility in making informed decisions regarding treatment based on 
dialogue with their patients.  After consensus is reached in these three areas, the workgroup will 
revise and distribute the guidelines to a wider audience for broader input. 
 
Some ACET members expressed reservations about unresolved issue 1 in which a decision 
has not been made on whether to consider capacity in the recommendation for any type of 
healthcare provider to screen FBP for LTBI.  The members emphasized that individual capacity 
of providers should be taken into account because internists, pediatricians and other physicians 
with no expertise in infectious diseases are not necessarily equipped to screen FBP for LTBI.  If 
consensus is reached not to consider individual capacity of providers, however, ACET advised 
the workgroup to recommend that healthcare providers give patients a written copy of their TB 
test results.  This guidance would resolve a capacity issue for providers who do not have 
electronic medical record systems that are linked to health departments. 
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Most ACET members expressed serious concerns about unresolved issue 3 in which a decision 
to test would no longer serve as a decision to treat.  The members strongly urged the workgroup 
to avoid decoupling TB screening and treatment in the guidelines.  The ACET members made 
additional suggestions and comments for the workgroup to consider and discuss during the 
consensus meeting. 
 
• The workgroup should review CDC’s published data that showed the environment 
places FBP at greater risk for TB rather than time of arrival in the United States.  The 
paper pointed out that FBP continue to be exposed to TB due to frequent visits to their 
countries of origin or relatives and friends who visit the United States, but are not 
screened for TB overseas. 
• The workgroup should take caution in not recommending LTBI screening of FBP from 
low-risk countries.  Canada, Sweden and other low-risk countries could have subgroups 
of FBP who are at high risk for TB, such as substance abusers, minorities and refugees. 
• The workgroup should attempt to compile data to determine the extent to which 
interferon-based tests versus TST with the Mantoux method are being used at this time. 
• The workgroup should explore the possibility of adding foreign-born HCP as another 
special population in the guidelines. 
• The workgroup should ensure that the foreign-born guidelines are consistent with other 
CDC guidance.  For example, the draft IGRA guidelines recommend IGRA as the 
preferred screening method for persons who have been vaccinated with BCG, while the 
workgroup has not yet reached consensus on whether the foreign-born guidelines 
should be permissive or specifically advocate for the use of IGRA in FBP. 
• The workgroup should use the consensus meeting as an opportunity to discuss payment 
of targeted testing of FBP in the context of healthcare reform. 
• CDC should update its 2000 guidelines for targeted testing and treatment of persons 
with LTBI to be consistent with the new foreign-born guidelines. 
• The workgroup should solicit input and obtain endorsement of the guidelines from 
professional associations whose members will be responsible for the implementation of 
the recommendations in routine practice.  Examples of these organizations include: 
— The Society of General and Internal Medicine and American Academy of Pediatrics 
for implementation of the guidelines by primary care physicians. 
— The American College Health Association for implementation of the guidelines by 
providers who screen foreign-born students for TB. 
— The foreign-born medical community for implementation of the guidelines by foreign-
born physicians with patient populations from India and other high-burden countries. 
 
Dr. Castro made two additional suggestions for the workgroup to consider and discuss during 
the consensus meeting.  First, Dr. Jerry Mazurek or Dr. Andrew Vernon, of DTBE, should be 
asked to make a presentation during the consensus meeting on the provisional guidelines for 
the use of IGRA.  Language in the current guidelines favors the use of IGRA in persons 
vaccinated with BCG.  Second, representatives from ATS and the Infectious Disease Society of 
America (IDSA) should be invited to the consensus meeting because both of these 
organizations played a critical role in developing the 2000 guidelines for targeted testing and 
treatment of persons with LTBI. 
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Drs. Fleenor and Katz confirmed that ACET’s concerns, comments and suggestions on the 
foreign-born guidelines would be discussed during the workgroup’s consensus meeting.  Dr. 
Fleenor also noted that the outcomes of the consensus meeting would be reported to ACET 
during the October 2009 meeting. 
 
BCG Workgroup.  Dr. Barbara Seaworth is an ACET member and chair of the workgroup.  She 
reported that the workgroup was formed in 2008 with an initial charge to review new literature 
on the efficacy of BCG and apply more recent data to update CDC’s 1996 BCG guidelines.  
During the March 2009 meeting, however, ACET unanimously adopted the following resolution.  
The workgroup’s charge would be modified to decrease the focus on the use of BCG and 
formulate more general recommendations on approaches to protect humanitarian and scientific 
travelers who travel from the United States to work in endemic areas of the world where MDR-/ 
XDR-TB exposure and infection would be more likely. 
 
In response to the modified charge, the workgroup expanded its membership to include experts 
from CDC’s DGMQ, Division of Healthcare Quality Promotion (DHQP), and Division of 
Respiratory Disease Studies in the National Institute for Occupational Safety and Health.  The 
workgroup also engaged Dr. Daniel Hoft as an expert reviewer for the BCG section of the 
guidelines.   
 
Dr. Seaworth outlined the workgroup’s proposed plan to fulfill its modified charge based on 
previous input from ACET and CDC.  The new title of the guidelines will be Screening and 
Infection Control Guidelines for Healthcare Workers and Volunteers Who Travel to Work in 
Healthcare Facilities in Regions in Which Drug-Resistant TB is Endemic.  The guidelines will be 
shortened to specifically focus on issues that are pertinent to screening and infection control for 
the prevention of MDR-/XDR-TB in HCP and other volunteers.  Emphasis will be placed on 
strategies for the management of persons who travel to high-risk areas to provide health care or 
humanitarian aid. 
 
BCG will be discussed in the guidelines as only one of several options for HCP and other 
volunteers to consider.  Other pertinent preventive measures that will be highlighted include 
infection control precautions, personal respiratory protection, education, airborne infection 
isolation rooms, and serial testing to monitor for new infections.  The BCG section will contain 
new data on the potential efficacy of BCG and a description of the benefits, contraindications 
and risks of vaccination.  Existing knowledge and data on the risks of BCG to HCP will be 
described as well.  The references will be updated as needed. 
 
The workgroup recognizes the need to resolve a number of concerns ACET raised during 
previous meetings.  The efficacy of BCG continues to be a source of debate.  Sufficient data 
have not been collected to date to formulate evidence-based recommendations, demonstrate 
actual risks to travelers, or provide guidance on the management and treatment of LTBI in HCP 
and other volunteers with possible MDR-TB.  The workgroup also has not determined the 
duration of exposure that might possibly be considered. 
 
The recommendations section of the guidelines will provide guidance in the following areas.  
The initial assessment prior to departure will focus on an evaluation of risk at specific sites, 
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education regarding measures to limit risk, fit testing with a personal respirator and education 
regarding its use, and provision of a respirator.  The assessment for LTBI or TB disease prior to 
departure will focus on TST and IGRA as screening methods.  The workgroup has not yet made 
a decision on whether LTBI treatment should be recommended prior to departure. 
 
Options for BCG vaccination will focus on education regarding risks and benefits as well as a 
discussion and documentation of contraindications.  The assessment upon return from travel 
will focus on repeating TST or IGRA if the prior test was negative and conducting an evaluation 
to exclude disease based on conversion of TST or IGRA results.  The workgroup has not yet 
made a decision on whether >1 drugs or which specific drugs should be recommended for 
treatment of newly acquired TB infection.  The guidelines will emphasize the critical need to 
collect additional data to answer these research questions. 
 
Dr. Seaworth concluded her update by requesting ACET’s guidance in two areas before the 
workgroup takes further action on revising the expanded guidelines.  The workgroup needs 
additional feedback from ACET to resolve concerns or opposing viewpoints that were raised 
during previous meetings.  The workgroup needs ACET’s input on whether the proposed plan to 
revise the expanded guidelines is appropriate. 
 
ACET commended Dr. Seaworth, Dr. Elsa Villarino, of DTBE, and other members of the 
workgroup for their dedication and commitment to this activity, particularly in light of the 
enormous amount of time and effort required to expand the guidelines from a narrow focus on 
BCG vaccination to a broader focus on TB prevention in endemic areas. 
 
ACET fully supported the workgroup’s proposed plan to revise the guidelines with a broader 
focus on the prevention of TB in HCP and other volunteers who travel to regions of the world 
where drug-resistant TB is endemic.  Due to the lack of evidence on BCG, ACET also was in 
favor of recommending BCG as an optional preventive measure.  Several ACET members 
pointed out the tremendous value in issuing the expanded guidelines.  Most notably, the 
practice of travel medicine is overwhelmingly poor in the United States with the exception of 
New York City and few other large jurisdictions. 
 
ACET advised the workgroup to seriously discuss the risks of issuing guidance to students who 
travel to areas of the world that are endemic for drug-resistant TB and need respiratory 
protection.  The guidelines should advise students to reconsider their plans to travel to these 
high-risk areas.  The guidelines also should provide a list of sites and other resources where 
students can be educated on potential health risks prior to travel. 
 
Dr. Fleenor closed the discussion by acknowledging ACET’s strong support for the workgroup to 
implement its proposed plan to revise the guidelines for TB prevention in HCP and other 
volunteers who travel to regions of the world where drug-resistant TB is endemic.  He confirmed 
that updates by the workgroup would continue to be placed on future agendas for ACET to 
provide ongoing input and guidance as various drafts of the guidelines are completed.  Dr. 
Castro confirmed that CDC would continue to provide the workgroup with staff support and 
other resources to revise the guidelines. 
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Ms. Bonnie Plikaytis, Acting Chief of MLB, provided an overview of MLB’s external peer review 
that would be held on August 21, 2009.  CDC’s 2002 peer review policy of research and 
scientific programs requires all research and scientific programs conducted or funded by CDC to 
undergo an external peer review at least once every five years to evaluate scientific and 
technical quality as part of the Board of Scientific Counselors (BSC) administered review of 
scientific programs. 
 
Ms. Plikaytis noted that Dr. Fleenor would serve as the chair of the MLB external peer review 
panel and the five panel members would represent the Coordinating Center for Infectious 
Diseases (CCID) BSC, Association of Public Health Laboratories (APHL), academia, and a state 
public health department. 
 
Ms. Plikaytis summarized the information MLB would present to the external review panel to 
inform its deliberations.  MLB’s workforce of 33 personnel includes 26 full-time equivalents, five 
ORISE Fellows, one American Society for Microbiology postdoctoral fellow, and one Emerging 
Infectious Diseases postdoctoral fellow. 
  
Of DTBE’s ~$12.3 million allocation to MLB in FY2009, ~$7.6 million was for cooperative 
agreements, ~$3 million was for employee salaries and benefits, ~$1.1 million was for the 
National Genotyping Service contract, $348,000 was for supplies and equipment, and $62,000 
was for travel.  MLB leveraged additional funding in FY2009 of $189,000 from the DTBE TB 
Leads Program, $100,000 from the Global AIDS Program, $120,000 from the Office of Antibiotic 
Resistance, and $50,000 from the Georgia Research Alliance. 
 
MLB’s organizational structure of the Reference Laboratory Team and Applied Research Team 
collaboratively conducts activities in six areas.  MLB designed the conventional laboratory and 
molecular diagnostic activities to serve as a reference laboratory for DST to U.S. public health 
laboratories and provide DST and genotyping support for DTBE studies.  MLB also uses these 
activities to identify non-tuberculous mycobacteria (NTM), but this service will be transferred to 
DHQP in the near future. 
 
MLB will launch a new service for molecular detection of drug resistance on September 1, 2009.  
DNA sequencing-based assays will be provided to detect mutations associated with drug 
resistance of rifampin, isoniazid (INH), amikacin, fluoroquinolones, kanamycin and capreomycin.  
MLB designed the platform to be easily expanded. 
 
MLB designed the laboratory capacity activity to provide oversight and administration of the 
laboratory component of TB cooperative agreements, train U.S. public health laboratory staff, 
conduct the model performance program for DST, and perform operational research by 
surveying the quality of TB services in public and private sector laboratories. 
 
Overview of the Mycobacteriology Laboratory Branch (MLB) External Peer Review 
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MLB uses this activity to secure funding and assist in planning co-located meetings sponsored 
by NTCA and APHL to assure that laboratory aspects of TB are included in TB control efforts.  
MLB also uses this activity to participate on the APHL TB Steering Committee.  MLB has 
assigned and funded a TB laboratory consultant for each state and jurisdiction to collaborate 
with program consultants in reviewing reports, conducting site visits and providing consultation 
as needed. 
 
MLB designed the molecular genetics activity to elucidate the mechanisms of drug resistance 
through several strategies.  DNA sequencing of ~320 isolates is performed to map mutations 
associated with drug resistance.  These data will provide a basis for interpreting sequencing 
results generated by MLB’s new molecular detection of drug resistance service.  A new 
mechanism was developed to detect low-level kanamycin resistance based on an over-
expression of acetyltransferase that inactivates the drug.  MLB has incorporated this 
mechanism into the new molecular detection of drug resistance service that will be launched in 
September 2009.  Studies on mechanisms of resistance to first- and second-line are ongoing 
with a focus on functional genetics and genomic sequencing of drug-resistant isolates. 
 
MLB designed the immunology and cell biology activity to evaluate Mycobacterium tuberculosis 
(M.tb) proteins for use as a second-generation TB vaccine.  Under this activity, MLB and the 
Emory Vaccine Center collaborated to identify four proteins that elicit promising immunogenicity 
and antigenicity profiles in the mouse model.  Protection studies that were initiated in February 
2009 in the mouse model to evaluate proteins are expected to be completed in late 2009 or 
early 2010.  The Georgia Research Alliance awarded funding to support this project and CCID 
filed a patent application in January 2009 to protect the intellectual property rights of the study. 
 
MLB designed the genotyping activity to support the National TB Genotyping Service contract 
that was renewed in October 2008 with an expanded focus on MIRU typing of isolates.  MLB 
also uses this activity to support Task Order 2 and TB Trials Consortium (TBTC) studies on 
human genotyping. 
 
MLB will target its future activities to two major areas.  In the “service component,” conventional 
DST and molecular detection of drug resistance for M.tb isolates will continue to be provided and 
services will be expanded as needed.  Education and training in laboratory practice and science 
will be provided to laboratory personnel, TB controllers and physicians to enhance understanding 
and accurate interpretation of molecular tests.  Oversight of the TB cooperative agreements and 
consultation to U.S. public health laboratories will continue to be provided.  Efforts will be made 
to strengthen U.S. mycobacteriology laboratory systems in collaboration with APHL. 
 
In the “research component,” translational and operational research will focus on implementing 
new diagnostic technologies and administering the comprehensive survey of laboratory practices 
and services in public and private sectors.  Laboratory methods to diagnose TB and MDR-/XDR-
TB and genotype M.tb isolates will be developed and evaluated.  Mechanisms of resistance and 
virulence factors for M.tb will continue to be characterized.  A second-generation TB vaccine will 
be produced and evaluated in a Phase I trial in collaboration with industry and other external 
partners. 
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Ms. Plikaytis concluded her overview by summarizing three key questions the MLB external peer 
review panel would be charged with answering.  One, are MLB’s activities and research agenda 
aligned with DTBE’s mission, goals, strategic priorities and core activities?  Two, what are the 
strengths and successes of MLB’s activities?  Three, what are the weaknesses and deficiencies 
of MLB’s activities, including any significant program or research gaps? 
 
Ms. Plikaytis added that the external peer review panel also would be asked to offer guidance 
on whether MLB should continue, discontinue, modify or add specific program and research 
activities to its existing portfolio.  After the panel submitted its report to DTBE four to six weeks 
after the external review, MLB and DTBE would produce a formal response.  MLB hopes to 
present a summary of the panel’s report to ACET during the October 2009 meeting. 
 
In preparation of transferring the service of identifying NTM, ACET advised MLB to provide state 
laboratories with background information on DHQP, including its mission and current capacity. 
 
Dr. Fleenor pointed out that based on CDC’s presentations and the workgroup reports on day 1 
of the meeting, the number of issues requiring ACET’s formal action during the business 
session on the following day was already extensive.  He agreed with Dr. Castro that ACET 
would have time to formulate, discuss and adopt resolutions for high-priority issues only, such 
as the role of TB programs in contributing to the H1N1 influenza response, while continuing to 
provide TB case management. 
 
To ensure that the business session was productive and efficient, Dr. Fleenor asked the ACET 
members to provide him with their “rankings” of high-priority issues before the meeting was 
reconvened on the following day.  He clarified that any topics the ACET members ranked as 
“low” would be deferred until the October 2009 meeting. 
 
With no further discussion or business brought before ACET, Dr. Fleenor recessed the meeting 
at 4:48 p.m. on July 14, 2009. 
 
 
 
 
 
Dr. Fleenor reconvened the ACET meeting at 8:31 a.m. on July 15, 2009 and yielded the floor to 
the first presenter. 
 
Dr. Vernon covered the following areas in his update.  TBTC was formed in 1998 with a mission 
to collaboratively conduct programmatically relevant clinical, laboratory and epidemiologic 
research on the diagnosis, clinical management and prevention of TB infection and disease.  
TBTC’s infrastructure includes 27 clinical sites in the United States, Canada, Brazil, South Africa 
and Spain. 
 
TBTC’s organizational structure includes a Steering Committee within the Executive Affairs 
Group to oversee daily functions and nine Executive Committees and workgroups to advance 
the scientific agenda.  NIH-funded AIDS Clinical Trials Groups, particularly the Community 
Update on TBTC 
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Programs for Clinical Research on AIDS and the AIDS Clinical Trials Group, were used as 
models to create TBTC’s formal bylaws. 
 
Major studies conducted in the current cycle of TBTC are highlighted as follows.  TBTC Study 
26 is a preventive therapy trial comparing a standard nine-month regimen of INH to a three-
month regimen of once weekly INH and rifapentine for treatment of LTBI.  The follow-up of 
Study 26 will end in December 2010 and the results will be presented in the spring of 2011. 
 
TBTC Study 29 is comparing a daily rifapentine regimen with doses of 450 or 600 milligrams 
five days per week to a standard rifampin regimen with the primary outcome of two-month 
culture conversion.  To date, ~200 patients of the total sample size of ~480 patients have been 
enrolled and two safety reviews have been completed.  Enrollment is expected to be completed 
by February 2010.  TBTC Study 31 is currently under development and will serve as a follow-on 
to Study 29.  Study 31 will be designed as a Phase III trial with a high-frequency rifapentine-
based regimen. 
 
TBTC Study 30 is an MDR-TB study with a low-dose linezolid regimen.  Challenges of the study 
include a number of implementation issues, such as development of the protocol, toxicity of 
second-line regimens, drug procurement, preparation of a placebo and reorganization of the 
laboratory.  Moreover, the Medicines Control Council required ~12 months to issue regulatory 
approvals to import drugs for use in the clinical trial.  Enrollment of patients in Study 30 is 
competing with the TMC-207 trial that is underway at the same site in Durbin, South Africa.  
DTBE and the CDC Emerging Infectious Disease Program agreed to support the study. 
DTBE acknowledges that existing guidelines on the treatment of LTBI and TB disease will need 
to be updated based on outcomes of ongoing TBTC trials.  However, the chair of the TBTC 
Advocacy and External Relations Committee engaged in dialogue with ATS and learned that no 
funds are available to develop and implement new Microbiology Tuberculosis and Pulmonary 
Infections projects in FY2009. 
 
DTBE is currently recompeting TBTC for the next ten-year cycle.  The Technical Evaluation 
Panel met in June 2009 and determined that a number of excellent proposals were submitted 
for the contract site component of TBTC.  CDC expects to announce the new TBTC awards in 
September 2009.  Several excellent proposals also were submitted for the ten-year 
recompetition of the Department of Veterans Affairs component of TBTC. 
 
DTBE is continuing to explore the possibility of developing a field station component for the next 
generation of TBTC.  However, efforts to advance TBTC with three components simultaneously 
are presenting both financial and data management challenges to DTBE.  For example, 
traditional contracting mechanisms that focus on the ability of grantees to present and document 
their capacity and experience does not support the approach of developing new TBTC sites in a 
substantial manner. 
 
TBTC, the Pan African Consortium for the Evaluation of Antituberculosis Antibiotics, Oflotub 
Consortium, AIDS Clinical Trials Group, MDR groups and other trial groups are conducting trials 
to accelerate the development of promising new TB agents, including TMC-207, OPC-67683, 
SQ-109, PA-824, PNU-480, AZ oxazolidinone, rifapentine, high-dose rifampin and moxifloxacin.  
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These TB trials will provide an opportunity for FDA, the European Medicines Agency and other 
national agencies to consider new or modify existing regulatory approaches to safely and 
effectively accelerate the development of promising new TB agents.  The TB Alliance and Bill 
and Melinda Gates Foundation have developed a joint proposal to open dialogue on new 
regulatory approaches. 
 
The FDA Anti-Infectives Advisory Panel held a meeting in June 2009 to consider criteria for 
approval of an MDR candidate.  FDA will convene a public meeting on July 30-31, 2009 to 
discuss issues regarding the design of clinical trials of antimycobacterial drugs for the treatment 
of TB.  NIH will convene a pediatric TB workshop on July 29, 2009. 
 
Dr. Vernon concluded his update by requesting ACET’s assistance in the following areas to 
strengthen the new ten-year cycle of TBTC.  ACET should adopt a formal resolution for ATS, 
CDC and IDSA to prepare for updating guidelines on the treatment of LTBI and TB disease 
based on results of the TBTC trials.  ACET should provide input to DTBE on conducting Phase 
IV evaluations in the United States, particularly for an LTBI regimen.  ACET should provide 
guidance on the development of new TBTC trial sites and offer strategies to ensure careful and 
efficient coordination between TBTC and other trial groups.  ACET should help to define the role 
and responsibilities of the public sector and other partners in the development of new TB drugs. 
 
ACET made suggestions for DTBE to consider in the new ten-year cycle of TBESC. DTBE 
should ensure that capacity is built to administer new drugs for TB and MDR-TB. 
 
Dr. Castro raised the possibility of ACET devoting a substantial portion of a future meeting to 
engage ATS, IDSA and experts from other professional societies to evaluate data from the 
ongoing TBTC trials and develop preliminary guidelines.  He noted that guidelines from a 
federal advisory committee with input from external experts could play a significant role in 
leveraging additional resources for TBTC and promoting the use of promising new TB agents. 
 
 
 
 
 
Dr. Katz reminded ACET that TBESC Task Order 23 was designed as a national study to 
identify determinants of early diagnosis, prevention and treatment of TB in the AA community.  
TB rates in U.S.-born AAs have been declining, but TB rates are still ~8 times higher in this 
population compared to U.S.-born whites.  The study will be conducted based on the hypothesis 
that delays in the diagnosis and treatment of active TB and LTBI are major determinants of 
higher rates of TB and a slower decline in rates among U.S.-born AAs. 
 
The goals of the study are to understand factors associated with diagnosis and treatment delays 
among AA to facilitate developing education programs for patients and providers; proposing 
performance goals and indicators for TB programs; and identifying missed opportunities for TB 
screening.  The objectives of the study are to recruit a sample size of 500 U.S.-born AAs and a 
comparison group of 175 U.S.-born whites.  In-depth interviews will be conducted and health 
department medical records of patients will be abstracted to measure the time between 
Update on TBESC Task Order 23 
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diagnosis and treatment in the study population; determine delays among patients, providers 
and TB programs; and assess the impact of delays on the spread of TB.  The study will be 
controlled for HIV, diabetes and other co-morbid conditions in the sample size. 
 
Questionnaires will be administered to both adults and children and a survey will be 
administered to TB programs.  The study will be conducted in eight urban and rural areas in 
Georgia, Maryland, New Jersey, New York City, North Carolina, Tennessee, Texas and Virginia.  
These sites were selected based on their large proportions of TB cases among U.S.-born AAs. 
 
DTBE has taken the following actions to date to conduct the study.  Initial approval for the study 
was obtained from 17 Institutional Review Boards.  Interviewers were trained in using the data 
abstraction forms and administering the questionnaires and surveys.  A data entry system was 
developed for the pilot project and an implementation plan was created for all eight sites.  
Recruitment of the pilot was initiated with the completion of 15 of 40 planned interviews. 
 
DTBE’s next steps will be to complete the pilot at all eight sites by the end of July 2009 and 
analyze data.  The questionnaires, data abstraction forms and implementation plan will be 
revised based on results of the pilot.  The study protocol will be resubmitted to Institutional 
Review Boards and recruitment for the full study will be initiated on September 1, 2009.  DTBE 
expects to complete the full study in September 2011. 
 
ACET made a number of suggestions for DTBE to consider in implementing the full study in 
September 2009. 
 
• DTBE should engage Dr. Kathleen McDavid Harrison, Associate Director of Disparities 
in NCHHSTP, to provide expertise on the SDH component of the study. 
• DTBE should design the study to focus on institutional differences among states in 
implementing the TB diagnostic process. 
• DTBE should use the study as an opportunity to perform modeling to identify variables 
for late health seeking behaviors among AAs and delays in diagnosis, such as racial 
segregation that serves as a barrier to care. 
• DTBE should make every effort to store serum and other specimens collected during the 
study for DNA analysis to inform future genetic studies.  These data could help to 
answer important research questions on the influence of ethnic factors in certain 
populations being susceptible to TB. 
 
 
 
 
 
Dr. Denise Garrett, Team Lead of the DTBE Epidemiology Team, covered the following areas in 
her update.  Of 28 TBESC studies that have been launched over the past eight years, seven 
have been completed, seven are nearly complete, ten are ongoing and four will be initiated in 
FY2009.  DTBE will convene a meeting in July 2009 with all TBESC principal investigators to 
discuss the status of each active study, identify potential barriers to and develop a plan of action 
for completion, and ensure adequate funding of ongoing studies. 
Update on TBESC 
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Major studies conducted in the current cycle of TBESC are highlighted as follows.  TBESC Task 
Order 9 focused on missed opportunities for the prevention of TB in FBP.  The objectives of the 
study were to describe the epidemiology of TB in FBP; identify barriers and opportunities for 
prevention; and inform the development of recommendations on immigration medical screening 
policies, TB control policies and TB surveillance practices.  Data from the study were used to 
estimate additional benefits from improved overseas screening. 
 
Prior to the study, only 33% of FBP with TB were immigrants or refugees who were eligible for 
overseas screening.  Of this population, 20% developed TB within one year of entry into the 
United States that suggested these persons had active TB upon arrival.  The study showed that 
more sensitive pre-entry screening measures would provide an additional benefit of 6.7% in 
detecting active TB in FBP upon their arrival to the United States.  The study further 
demonstrated that overseas screening of TB disease would play an important, but limited role in 
further reduction of TB rates in the United States.  LTBI screening of foreign-born residents in 
the United States might be a more effective approach to accelerate reduction of TB in FBP. 
 
TBESC Task Order 13 was a three-phase study that focused on factors associated with 
acceptance of and adherence to LTBI treatment.  Phase 1 was designed to estimate the impact 
of LTBI treatment.  Clinics in catchment areas that treat LTBI were identified and these results 
were extrapolated to the U.S. population.  The study concluded that LTBI treatment prevented 
10,000 TB cases in 2002. 
 
Phase 2 was designed to estimate the proportion of LTBI patients who complete treatment.  
Based on a chart review of 2,385 patients who were offered treatment, 83% accepted treatment 
and 47% completed treatment.  The study found an association between shorter regimens and 
completion of treatment.  Phase 3 is ongoing and was designed as a prospective cohort study of 
factors associated with acceptance of and completion of LTBI treatment from 2007-2009. 
 
TBESC Task Order 18 evaluated IGRA in the diagnosis of LTBI in HCP.  The objectives of the 
study were to compare QuantiFERON, T-SPOT and TST in the detection of LTBI in HCP by 
examining conversion and reversion rates, the ability to reproduce simultaneous tests, the ability 
to repeat serial tests, acceptability of the tests, and the costs and cost-effectiveness of the tests. 
 
Baseline positive rates of the three tests ranged from 6.9%-8.9%.  Intra-laboratory variability in 
the same draws ranged from 4%-11% with QuantiFERON and T-SPOT.  Conversion rates of 
IGRA were six times higher than TST at the six-month follow-up.  The study concluded that 
cutoff points for conversion should be further evaluated and alternative criteria need to be 
developed for conversion and reversion rates of tests. 
 
A recent analysis focusing on the impact of recent TST on IGRA results showed that TST might 
boost a subsequent IGRA because IGRA boosting occurs within two weeks of TST.  The 
analysis concluded that TST boosting of IGRA results could affect interpretation of serial testing.  
These data could be helpful in informing the development of guidelines on the use of TST with 
IGRA.  DTBE noted that the United Kingdom and Canada currently recommend confirmatory 
IGRA for TST-positive results. 
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DTBE is currently preparing for the new cycle of TBESC and is extremely pleased with the 
valuable studies that were conducted in the first ten-year cycle to date.  DTBE will apply a 
number of lessons learned to improve TBESC in the future, such as the importance of a solid 
data management system, the need to take advantage of the full strength of TBESC, the need 
to consider the impact of TBESC research, and the need to narrow the TBESC research focus. 
 
Based on these lessons learned, DTBE will make the following changes in the new cycle of 
TBESC.  Multiple oversight committees will be replaced with one Board of Directors.  Numerous 
protocols will be replaced with one standard protocol with sub-studies.  The requirement for 
TBESC sites to compete for studies will be replaced with a new policy in which all sites will 
participate in the main study.  The decentralized data management system will be replaced with 
a centralized system.  Multiple research topics will be replaced with one research topic. 
 
To obtain external input on the TBESC recompetition process, DTBE formed a Strategic 
Planning Workgroup.  The workgroup is represented by two ACET members, TB controllers, 
and other domestic and international experts in the fields of science, public health and TB 
research.  The workgroup agreed that the new cycle of TBESC should focus on LTBI and 
proposed several possible interventions, such as screening of high-risk populations, targeted 
testing and treatment, contact and outbreak investigations, diagnostics, treatment and 
adherence.  Regardless of the research topic that is ultimately selected for the new cycle of 
TBESC, a registry match outcome will be created to follow-up patients for two years. 
 
DTBE’s next steps in the TBESC recompetition process are to develop proposals of potential 
research topics into a detailed research plan, select the new TBESC research topic and 
establish rigorous criteria, issue a request for application for new sites, and select and fund the 
new TBESC sites by September 2010.  During the last year of the current cycle of TBESC, old 
and new sites will overlap.  Because the new TBESC awards will not be announced until 
September 2010, Dr. Garrett explained that she is prohibited from disclosing the names of the 
Strategic Planning Workgroup members, identifying the new TBESC research topic, or 
discussing any other confidential aspects of the recompetition process. 
 
Dr. Castro clarified that ACET is welcome to propose names of other persons who could serve 
on the Strategic Planning Workgroup to represent affected communities so long as these 
individuals are impartial and have no conflict of interest in the TBESC recompetition process. 
 
 
 
 
 
Dr. Mary Reichler, of DBTE, provided an update on TBESC Task Order 2 that was designed as 
a prospective evaluation of epidemiologic, genetic and immunologic factors associated with TB 
infection and disease.  The natural history of TB begins with a TB patient who infects an 
exposed contact.  Of the exposed contacts, 60% will remain TST-negative, while 40% will 
develop LTBI and become TST-positive.  Of the TST-positive persons, 10% will develop TB.  Of 
these TB patients, 15% will develop severe TB that is difficult to treat.  The determinants of TB 
Update on TBESC Task Order 2 
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transmission include exposure, infectiousness of patients, host factors, and the environment.  
These determinants result in TB disease that eventually could lead to outbreaks. 
 
To better understand the epidemiology of TB, dynamics of transmission and progression to TB 
disease, DTBE launched Task Order 2 at nine TBESC sites.  The objectives of this large multi-
site study are to evaluate contact investigation outcomes, identify epidemiologic risk factors for 
M.tb transmission, identify genetic determinants of susceptibility to infection and disease, and 
evaluate surrogate markers of protective immune response to M.tb. 
 
The study design includes culture-positive pulmonary TB cases >15 years of age, all contacts of 
these cases, interviews with both cases and contacts, environmental assessments, TB and HIV 
registry matches, and collection of whole blood to test three cytokine surrogate markers and 52 
genetic polymorphisms. 
 
U.S.-born, Canadian-born and foreign-populations enrolled in the study were well characterized 
with regard to the frequency, duration and timing of TB exposure, the infectiousness of TB 
cases, the susceptibility of hosts and environmental exposures.  The U.S.-born and Canadian-
born populations had no BCG vaccination.  The study population had a low risk of continual 
exposure to M.tb.  Enrollment of 948 TB cases and 5,491 contacts has been completed.  To 
date, 1,986 genetic specimens and 2,250 immunologic specimens have been collected; 32 of 
52 genetic polymorphisms have been tested; and all three cytokine surrogate markers have 
been tested. 
 
DTBE formed four writing groups with 17 manuscript teams.  The Contact Investigation 
Outcomes Writing Group will produce five manuscripts; the Epidemiologic Risk Factors Writing 
Group will produce three manuscripts; the Immunologic Surrogate Markers Writing Group will 
produce five manuscripts; and the Genetic Determinants Writing Group will produce four 
manuscripts.  Preliminary data analyses were performed on epidemiologic, genetic and 
immunologic outcomes.  Of eight abstracts that were developed, five have been presented and 
three were recently submitted for presentation at major international meetings.  DTBE expects 
to produce the results of 10-12 additional analyses in the next 6-12 months. 
 
Preliminary results of a TBESC Task Order 2 sub-study were recently presented during the May 
2009 ATS meeting and are highlighted as follows.  The sub-study emphasized that close 
contacts of infectious TB patients are at high risk of LTBI and TB disease.  The lifetime risk of 
TB after recent exposure is estimated to be 10%, but 50% of this risk occurs in the first two 
years after exposure.  A series of retrospective studies published in 2000-2003 documented that 
the reported proportion of contacts of infectious TB patients with TB disease ranges from 1%-
2% in low-incidence settings. 
 
The timing and rates of TB disease among recently exposed contacts are not well established.  
The relative proportion of TB cases among exposed contacts that can still be prevented at the 
time contact investigations are initiated is unknown.  In an effort to fill these data gaps, the 
TBESC Task Order 2 sub-study was designed to achieve four key objectives.  The yield of 
contact investigations for new cases of active TB would be determined.  The rates and timing 
between TB disease among contacts and active pulmonary TB patients would be evaluated.  
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The number of TB cases among contacts that could still be prevented at the time of contact 
investigations would be determined.  Epidemiologic characteristics of contacts with newly 
diagnosed TB disease would be described. 
 
For purposes of the sub-study, a “TB contact-case” was defined as culture-confirmed or 
clinically diagnosed pulmonary or extrapulmonary TB in a contact to an enrolled culture-
confirmed TB patient.  Dates of treatment initiation were used to define the onset of TB disease 
in TB patients and contacts.  Dates of the first TST or first chest radiograph if no TST was 
performed were used to define the timing of contact investigations. 
 
 “Preventable” cases were defined as contact-cases with treatment >30 days after TB patient 
treatment initiation with no evidence of TB disease at an initial timely evaluation.  “Possibly 
preventable” cases were defined as contact-cases with treatment >30 days after TB patient 
treatment with delayed or no initial evaluation and a subsequent abnormal chest x-ray.  “Not 
preventable” cases were defined as contact-cases with treatment before or <30 days after TB 
patient treatment initiation or an abnormal chest x-ray <30 days after TB patient treatment 
initiation. 
 
Rates of TB disease among contacts were calculated using the number of contacts with TB 
during the observation interval as the numerator and the total number of priority 1 contacts 
multiplied by the observation interval as the denominator multiplied by 1,000.  This calculation 
provided rates per 1,000 person-months. 
 
Of 4,544 priority 1 contacts, 70% completed TST screening, 8% were not screened, 6% had 
prior TB or TST-positive results, and 16% had no post-exposure TST.  Of 3,225 priority 1 
contacts who completed screening, 51% had TST-negative results, 6% were documented 
converters, 38% initially had TST-positive results, and 5% had active TB.  An analysis of the 
timing of TB among contacts from TB patient treatment initiation showed that the largest number 
of contact-cases were within the 1- to 30-day interval after TB treatment. 
 
A registry match at two years detected 39 additional cases for a total of 199 TB cases among 
contacts.  Of 199 contact-cases identified during the investigation and registry match, 45% had 
secondary TB; 40% had co-prevalent TB occurring either within one month before or one month 
after diagnosis of the index case; and 15% had prior TB occurring before diagnosis of the index 
case. 
 
An analysis was performed to determine TB case rates among 4,544 contacts by interval from 
TB patient treatment initiation.  The analysis showed that the TB case rate of 12.1/1,000 person-
months was highest in the 1- to 30-day interval with 55 cases.  Case rates from TB patient 
treatment initiation remained high at 7.9/1,000 person-months in the 31- to 60-day interval with 
36 cases; 4.2/1,000 person-months in the 61- to 90-day interval with 19 cases; and 0.7/1,000 
person-months in the 91- to 180-day interval with 10 cases. 
 
The case rate from TB patient treatment initiation of 0.07/1,000 person-months was lowest in 
the 366- to 730-day interval with four cases.  Recalculation of these results showed an 
extraordinarily high case rate of 2,971/100,000 population in the 1- to 365-day interval after TB 
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treatment of the index case and an elevated case rate of 88/100,000 population in the 366- to 
730-day interval. 
  
Of 90 contacts with secondary TB detected in the initial contact investigation, 74% had TB at the 
time of initial screening, 12% were TST-positive, 4% were not screened and later developed TB, 
3% were TST-negative and later developed TB, 2% were converters with no evidence of TB at 
initial evaluation, 2% had incomplete screening, and 2% had prior TB or TST-positive results.  
Of 199 TB cases among contacts detected in the contact investigation, 63% were not 
preventable, 23% were possibly preventable, and 14% were preventable.  A preliminary 
analysis of the epidemiologic results showed increased rates of progression to TB disease in 
AAs compared to whites.  Of children enrolled in the study, 50% rapidly developed TB within the 
first three months. 
 
Overall, the TBESC Task Order 2 sub-study showed that contact investigations have a high 
yield for new TB cases.  Relatively few of these new TB cases can be prevented, but the 
development of interventions to shorten the time between positive TST results and chest 
radiograph could increase the number of TB cases prevented.  Moreover, contact investigations 
are an extremely important approach to identifying co-prevalent and secondary TB cases and 
placing these cases on treatment to prevent further transmission. 
 
TB case detection rates among exposed contacts are highest in the month following TB patient 
diagnosis.  These rates steadily fall, but remain elevated for at least two years.  Additional 
operational research should be conducted on contact investigations and risk factors for TB 
transmission to learn more about the timing and rates of TB infection and disease and assist 
programs in developing algorithms to prioritize contact investigations. 
 
ACET made two key suggestions for DTBE to consider in refining TBESC Task Order 2 and 
presenting data from these studies.  First, DTBE should design a new TBESC sub-study to 
determine factors that would encourage contacts to present for TB testing more quickly.  
Results of this study would be particularly helpful to local public health departments. 
 
Second, DTBE should frame the context of TBESC Task Order 2 to ensure that data are 
presented in a positive manner.  For example, programs might view contact investigations as 
unnecessary if only a “relatively few” number of new TB cases can be prevented.  DTBE should 
emphasize that contact investigations are a key case finding tool in helping to reduce both TB 
illness and secondary cases. 
 
Dr. Castro further advised DTBE to use results of TBESC Task Order 2 to conduct a stratified 
analysis that specifically focuses on the issue of race/ethnicity.  This approach could inform 
TBESC Task Order 23 that is being designed to identify determinants of early diagnosis, 
prevention and treatment of TB in the AA community. 
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Dr. Jan Gheuens is the Senior Program Officer for TB at the Bill and Melinda Gates Foundation 
and served as the keynote speaker during the ACET meeting.  He pointed out that the Gates 
Foundation has played a critical role in the dramatic evolvement of TB research and 
development (R&D) over the past seven years.  In 2002, only a few credible products had actual 
development plans in the product component of TB R&D.  Industry-style programs were minimal 
and scattered in the process component of TB R&D.  The small, but active group of TB 
researchers was academically focused in the research component of TB R&D. 
 
An overarching vision was established to strengthen the product, process and research 
components of TB R&D.  TB-specific product development partnerships (PDPs) would be 
formed to develop products and a process.  The Gates Foundation “Grand Challenges and 
Innovations Program” would encourage scientific engagement.  Several efforts have been made 
to date to achieve this vision.  A more credible and industry-style development plan was 
designed for the product component of TB R&D.  A rational approval process was created for 
the process component of TB R&D.  The small, but active group of TB researchers was 
enhanced with a more solid network and a stronger focus for the research component of TB 
R&D. 
 
Of the Gates Foundation’s total TB investment of $768 million, ~$587 million is devoted to TB 
drugs, vaccines and diagnostics.  A portion of this investment has been targeted to new tools 
through the development of three TB-specific PDPs.  The Aeras Global TB Vaccine Foundation 
develops, tests, characterizes, licenses, manufactures and distributes at least one new TB 
vaccine regimen for infants and adolescents and ensure its availability to all persons in need. 
 
The Foundation for Innovative New Diagnostics ensures equitable access to high-quality 
diagnosis worldwide and drives the development and implementation of accurate and affordable 
diagnostic tests that are appropriate to patient care in low-resource settings.  The Global 
Alliance for TB Drug Development (GATB) ensures widespread availability of affordable, faster 
and better TB drug regimens that will advance global health and prosperity. 
 
TB stakeholders recognize that a truly novel TB regimen might be licensed in 2018 based on 
drugs in the pre-clinical and clinical development stages at this time.  Based on a number of 
critical trends, the need for new combination therapies is more compelling than individual new 
drugs.  Drug-resistant TB has emerged as an important issue over the past few years.  Current 
second-line treatment regimens are impractical and difficult to scale-up.  The risk for inducing 
resistance to a new drug occurs shortly after introduction. 
 
Classical sequential development of a TB regimen cannot be achieved.  The current four-drug 
regimens were empirically developed with a standard that was established in the 1970s.  The 
individual contribution of each drug to the entire TB regimen is not understood.  The sequential 
development of a new TB combination would require decades based on the current state of TB 
clinical trial methodologies. 
 
Overview of the Critical Path to TB Drug Regimens Initiative 
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The Gates Foundation met with FDA to discuss regulatory challenges to the development of TB 
drug regimens.  For example, limited availability of biomarkers hinders the development of 
vaccines, makes vaccine development fully empirical, complicates assessments of vaccine trial 
endpoints, and increases the difficultly of clinical development.  Outcome endpoints produced 
after one or two years of TB clinical trials are used in Phase III studies.  With this approach, 
failure to cure and relapse rates are combined.  All unfavorable outcomes, including lost to 
follow-up rates and deaths from all causes, are combined as well. 
 
Bacterial endpoints, such as serial sputum colony counts and sputum conversion rates, are 
used in Phase I and II studies.  The Gates Foundation and FDA discussed the possibility of 
whether bacteriological endpoints could be qualified to support approval.  To address drug-
resistant TB, an FDA advisory committee recently recommended the acceptance of sputum 
conversion for approval under Subpart H that would require an additional confirmatory study 
after approval of a TB drug regimen.  However, this recommendation did not address drug-
sensitive TB. 
 
Despite these challenges, opportunities exist to develop TB drug regimens because nine new 
TB drug candidates representing various biological classes are in pre-clinical or clinical stages 
at this time.  The current list of TB drug candidates is expected to be dynamic as new 
compounds will be selected, while others might fail.  The Gates Foundation recognizes that four 
key questions must be answered to determine whether the development of TB drug regimens is 
actually feasible. 
 
First, are companies with TB drug candidates willing to test their pre-approval compounds in 
combination with other experimental compounds?  Historically, industry has been reluctant to 
take this approach based on legal, antitrust and safety concerns.  For example, a pre-approval 
compound might taint another compound.  Second, has a regulatory pathway to approval been 
established?  Regulations for the development of drug regimens exist at this time.  The role of 
each individual component in a drug regimen must be known, but acceptable evidence to fill this 
data gap in TB has not been collected to date. 
 
Third, what is the state of TB science to support this approach and regulatory decision-making?  
The predictive value of pre-clinical in vitro and in vivo studies is uncertain.  The ability to 
customarily accept endpoints for Phase II and III studies on drug-sensitive TB and MDR-/XDR-
TB is unknown.  More data are needed to address the limited availability of biomarkers.  Fourth, 
what mechanisms are available to fund this effort?  TB drugs have limited commercial value for 
large companies.  No company can afford or is willing to fund completion of projects, including 
Phase III studies.  Traditional donor funds could not adequately support Phase III programs. 
 
Due to the strong belief that the development of TB drug regimens can be achieved, a number 
of partners are currently in the planning stage of designing the Critical Path to TB Drug 
Regimens (CPTR) Initiative.  This collaborative effort aims to accelerate the development of 
new, safe and highly-effective regimens for TB by early combination testing.  During a closed 
meeting in June 2009, the Gates Foundation, NIH, FDA, Critical Path Institute (C-Path), and 
four of eight companies with TB drug candidates agreed to collaborate in CPTR. 
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The partners plan to expand CPTR in the future to include patient representatives, scientific 
advisors from academia and government agencies, and additional regulatory agencies and 
organizations at domestic and international levels to provide expertise, leverage additional 
funding and facilitate programmatic implementation through networks and organizations.  Due to 
the large investment that will be required by both public and private sectors in the TB 
community, the partners are aware of the need to establish a solid funding coalition to support 
CPTR. 
 
The mission and purpose of two of the eight current CPTR partners are outlined as follows.  
Partner 1 is FDA’s Critical Path Initiative (CPI) that was established to innovate science and 
tools and define a rigorous evidence base for regulatory decisions based on new science rather 
than shortcuts.  CPI has a simple concept, but is difficult to implement.  FDA published 76 CPI 
models in 2006, but these solutions are only effective based on adoption by FDA review 
divisions and other authorities.  Although the CPI Office spans across most of FDA’s centers, 
CPI’s applied science that could lead to better and faster regulatory decision-making receives 
relatively little funding.   
 
FDA’s key CPI models are highlighted as follows.  The Predictive Safety Testing Consortium 
includes 16 companies and three academic groups that are organized as nephrotoxicity, 
hepatotoxicity and other organ toxicity workgroups.  CDISC is a set of worldwide data standards 
that are supported by 250 member organizations to enhance electronic acquisition, exchange, 
submission and archival of clinical data. 
 
QSAR is a computational toxicology model that uses all chemical structures and all toxicology 
data FDA has reviewed to date.  This model has the ability to predict carcinogenicity, genetic 
toxicity, reproductive toxicity and development toxicity for new structures if these structures are 
related to known outcomes.  SENTINEL is a new approach to active safety surveillance. 
 
Partner 2 is C-Path that is a non-profit organization with a mission of organizing and managing 
FDA’s CPI projects.  C-Path created innovative methods for highly-competitive companies and 
regulatory agencies to share pre-competitive data and knowledge.  C-Path’s success is based 
on its creation and management of formal legal consortia with academic advisors, regulatory 
agency representatives, 500 participating scientists from 26 pharmaceutical companies, and six 
patient advocacy organizations. 
 
C-Path developed a three-pronged approach to fulfill its mission:  (1) develop a legal agreement 
to enable rapid, broad and open sharing of scientific data and knowledge by all parties; (2) 
reach scientific consensus among scientists from industry, academia and regulatory agencies 
on preferred testing methods of new products; and (3) obtain mutual acceptance of innovative 
testing methods, such as FDA-qualified biomarkers. 
 
To date, the CPTR partners have broadly communicated the initiative to TB stakeholders and 
proposed the following process.  A consortium would be formed similar to other CPI projects.  
C-Path would organize and manage the consortium.  The Gates Foundation would retain its role 
as a catalyst and convener, but would not have responsibility for the operation and oversight of 
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CPTR.  GATB and companies with TB drug candidates would form partnerships based on the 
production of promising data. 
 
The next steps to advance CPTR are to convene a meeting to clarify the scope of CPTR; outline 
the structure, roles and operating principles of the consortium; define various work streams; and 
identify “low-hanging” activities the partners could immediately initiate.  The meeting also will 
provide an opportunity for the CPTR partners to focus on clinical development plans and study 
designs; site capacity, regulatory capacity and logistical issues; and acceleration of applied 
science.  The CPTR partners will hold an additional meeting to conduct an in-depth review of 
currently available data on different drugs and their backups.  The CPTR partners also would 
form a workgroup to identify potential solutions to fund the development of TB drug regimens at 
$500-$600 million per year. 
 
The partners have agreed that “success” of CPTR will be defined based on the following 
outcomes.  The CPTR approach will be established as the gold standard for rapid, safe and 
efficient evaluation and development of new TB drug combinations.  Consensus-based and 
validated methods will be designed to test new TB drugs individually and in combinations that 
maximize learning and minimize delay. 
 
Novel regimens of TB drugs for treatment of drug-sensitive and drug-resistant disease will be 
developed, approved by regulatory agencies and endorsed by WHO.  Novel biomarkers for TB 
that are qualified for use in TB productive development will be created.  Diagnostic tests for TB 
will be designed and approved by regulatory agencies. 
 
Overall, a new era for TB product development has begun.  GATB, companies with TB drug 
candidates and other TB stakeholders have expressed strong enthusiasm and support for 
advancing from the development of individual TB drugs to TB regimens.  Because the partners 
are still in the planning stage of determining whether CPTR will serve as the collaborative effort 
to enable rapid development of TB regimens, Dr. Gheuens emphasized that ACET’s valuable 
input and expertise would be welcome at this point. 
 
Due to time constraints, Dr. Fleenor exercised the chair’s prerogative and tabled ACET’s 
comments and suggestions on Dr. Gheuens’ presentation until the discussion period following 
the next presentation. 
 
 
 
 
 
NIH/National Institute of Allergy and Infectious Diseases (NIAID).  Dr. Christine Sizemore is 
Chief of the TB, Leprosy and Other Mycobacterial Diseases Section of NIAID.  She explained 
that NIH is a biomedical research institution with 27 institutes and centers.  NIAID has lead 
responsibility for TB biomedical research at NIH and is the largest global funder of this activity.  
Other NIH institutes that play a significant role in TB science include the National Heart, Lung 
and Blood Institute, Fogarty International Center, and National Institute of Child Health and 
Human Development. 
Update on the Role of Federal Agencies in Global TB Control and Research 
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NIH’s mission is to help lead the way toward important medical discoveries that improve the 
health of individuals and save lives.  NIAID supports NIH’s mission in two major areas:  (1) 
conducting and supporting research to study the cause, diagnosis, treatment and prevention of 
infections, immunologic and allergic diseases and (2) providing critical resources to fill gaps in 
basic, translational and clinical research. 
 
Of NIAID’s ~$115 million TB research budget, 10% is devoted to intramural research conducted 
by NIAID and 90% is devoted to extramural research conducted in both U.S. and international 
settings by universities, pharmaceutical companies, individual investigators, public-private 
partnerships, research organizations and small businesses.  Of NIAID’s ~$115 million TB 
research budget, basic research accounts for 57%, drug development accounts for 20%, 
vaccine development accounts for 12% and diagnostics account for 11%. 
 
All NIAID extramural research activities are legally required to undergo a solicited or unsolicited 
research grant application process.  Applications are evaluated based on a thorough scientific 
peer review and scoring process.  Funding decisions are based on the merit and score of each 
application.  NIAID also awards funds through specific solicitations and contracts to support 
research infrastructures, research support services and pre-clinical development activities. 
 
NIAID established its four TB program priorities based on a translational research paradigm.  
Fundamental science focuses on host-pathogen interactions in immunology, microbiology and 
tools.  Translational science focuses on drugs, vaccines and diagnostic candidates to support 
discovery, pre-clinical validation and the selection of candidates.  Clinical studies focus on 
pathogenesis, disease, immune markers, HIV/TB co-infection, and clinical trials of new 
candidates and regimens.  Research support focuses on TB-specific and generic contracts 
across NIAID for research reagents, product testing, models, pre-clinical support and training. 
 
NIAID has a number of “hand-off” partners and beneficiaries to facilitate its translational 
research paradigm.  Grants and contracts are awarded to global biomedical TB research 
organizations and Gates-funded programs to conduct discovery research.  Solicited grants and 
contracts are awarded to pharmaceutical and biotech companies, the Stop TB Partnership and 
Gates-funded programs to conduct translational research. 
 
Contracts and solicited grants are awarded to small businesses in the United States and 
academic institutions to conduct pre-clinical testing.  Contracts and intramural grants are 
awarded to small businesses, pharmaceutical companies and CDC to conduct clinical trials and 
studies domestically.  Contracts and intramural grants are awarded to Gates-funded programs, 
pharmaceutical and biotech companies, CDC, the U.S. Agency for International Development 
(USAID), and the European and Developing Countries Clinical Trials Partnership to conduct 
clinical trials and studies internationally. 
 
CDC.  Dr. Kevin Cain is the TB/HIV Team Lead for the DTBE International Research and 
Program Branch.  He explained that CDC’s global TB research portfolio is funded by two major 
sources.  The DTBE Office of the Director provides supplies, equipment and salaries for core 
headquarters staff and 2.5 field staff; ~$1.3 million per year for the Botswana Field Station; and 
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$152,000 per year for travel funds.  The DTBE Office of the Director also uses cooperative 
agreements to allocate $176,380 per year to WHO and $166,303 to the International Union 
Against Tuberculosis and Lung Disease.  Through an interagency agreement with USAID, CDC 
receives ~$3.8 million per year from global and regional bureaus and country-specific missions. 
 
CDC’s areas of focus in its global TB research portfolio are to decrease the incidence of U.S. 
foreign-born TB cases and contribute to international efforts led by the Stop TB Partnership.  
The international efforts are designed to strengthen national TB control programs; mitigate the 
impact of TB/HIV; prevent the emergence and improve detection, diagnosis and treatment of 
drug-resistant TB; and address infection control in institutions and communities. 
 
CDC’s global TB research activities focus on two major areas.  Programmatically relevant 
operational and epidemiological research and training are conducted to strengthen TB control 
efforts, facilitate policy changes, and build capacity within national TB control programs through 
technical assistance.  Programmatically relevant clinical and diagnostic studies are conducted 
as well.  These activities are conducted in a limited number of countries due to the branch’s 
small staff and level of funding. 
 
CDC’s criteria to conduct global TB research activities in certain countries are based on 
strategic interest, such as those that contribute to U.S. foreign-born TB cases; countries with a 
high burden of TB; or countries with unique opportunities to conduct important research to 
inform global policy.  Based on 2006 data, the top ten countries contributing to foreign-born TB 
cases in the United States were Mexico, Vietnam, India, China, Haiti, Guatemala, South Korea, 
Ethiopia, Peru and the Philippines.  CDC has ongoing projects and activities in eight of these 
top ten countries as well as 12 of 22 high-burden TB countries. 
 
Examples of CDC’s global TB research and epidemiological studies are highlighted as follows.  
A clinical trial in Botswana is underway to evaluate the impact of INH preventive therapy on the 
prevention of active TB disease in patients with HIV.  The clinical trial is comparing a six-month 
and a continuous three-year regimen of INH preventive therapy.  Results of the clinical trial will 
play an important role in informing international policy. 
 
A large TB/HIV study in three countries in Southeast Asia with 2,000 patients examined the role 
of intensified case finding to improve the diagnosis of TB in HIV-infected persons.  Different 
screening approaches in adults and children were evaluated.  The three countries used results 
of the study to change screening policies.  WHO has included CDC’s study in an ongoing meta-
analysis of multiple studies to inform the development of recommendations in which chronic 
cough along with other symptoms would be used to screen for TB. 
 
CDC evaluated new rapid diagnostics, including a line probe assay for rapid diagnosis of TB 
and rapid MDR-TB diagnostics, to determine their effectiveness in actual practice.  CDC is 
conducting a large MDR-TB study in multiple countries focusing on preserving effective TB 
treatment for second-line drugs.  CDC is conducting a number of activities to enhance national 
TB programs, including an evaluation of TB screening practices among pediatric TB suspects 
and patients and an assessment of guidelines for diagnosis of smear-negative TB.  CDC is 
continuing its research and epidemiologic studies to better understand the epidemiology of TB 
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in FBP in the United States and also to influence infection control policies, particularly with 
respect to the risk for TB among HCP in outpatient HIV care settings. 
 
Department of Defense (DoD).  Dr. Sizemore presented the overview on behalf of Col. Naomi 
Aronson who was unable to attend the meeting.  Col. Aronson is the ACET ex-officio member 
for DoD as well as a Professor of Medicine and Director of the Infectious Diseases Division at 
the DoD Uniformed Services University of the Health Sciences.  Based on 1998-2005 data, the 
rate of active TB of 1.4/100,000 in the military population was lower then the age-adjusted rate 
in the U.S. population.  However, DoD noted a higher rate of TB outbreaks on Navy shipboards 
and similar risk factors for TB between the military and U.S. populations, such as foreign-born, 
non-white and HIV-positive persons. 
 
DoD is an expert in purified protein derivative (PPD) testing and performs 250,000 PPD tests in 
new accessions annually and 500,000 PPD tests each year overall.  DoD is now moving toward 
targeted TB testing of enlisted personnel who return from deployments.  DoD’s TB activities 
focus on three major areas.  Clinical care is provided to beneficiaries through screening for LTBI 
and treatment of active disease.  The military treats ~20,000 persons for LTBI each year. 
 
DoD conducts TB research, but this activity has no focused program or devoted funding.  
However, DoD’s TB research makes a significant contribution to LTBI diagnostics and TB/HIV 
co-infection, enhancement of laboratory capacity, and the development of best practices for TB 
control in the military population.  DoD performs surveillance through its large network of military 
bases worldwide.  For example, DoD is currently comparing various technologies, such as 
surveys, PPD testing and ELISPOT assays, to screen for new TB infections and LTBI in Fort 
Jackson, South Carolina. 
 
The U.S. Army and Navy have a strong international presence with overseas medical research 
laboratories in Egypt, Indonesia, Kenya, Peru and Thailand.  DoD’s collaborations with federal 
partners for other infectious diseases are important to TB.  The U.S. Military HIV Research 
Program partners with the President’s Emergency Plan for AIDS Relief to provide HIV treatment 
services for military and civilian personnel in Africa.  DoD’s medical capabilities play a critical 
role in the global fight against HIV.  DoD is exploring the possibility of using its existing influenza 
surveillance network to facilitate the collection of additional respiratory specimens, surveillance 
and diagnosis of TB and drug-resistant TB. 
 
USAID.  Dr. Sizemore presented the overview on behalf of Dr. Christy Hanson, a TB Research 
Advisor in USAID, who was unable to attend the meeting.  Of USAID’s $162 million TB budget, 
~$116 million is devoted to country programs, ~$22 million is devoted to global leadership 
activities, ~$15 million is devoted to the Global TB Drug Facility, and ~$9 million is devoted to 
the development of new tools and approaches. 
 
USAID conducts TB activities in 19 focus countries that account for 61% of the global TB 
burden as well as 17 additional countries.  USAID presented its 2006 research strategy to 
Congress to emphasize the comparative advantage of its field presence and highlight its five 
key focus areas:  (1) research with programmatic implications within three to five years; (2) 
research to bridge product development after NIH studies for implementation in the field; (3) 
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studies with global and national policy implications; (4) late stage trials; and (5) operational 
research. 
 
USAID is currently conducting four flagship TB research projects.  USAID is conducting clinical 
trials focusing on TB re-treatment regimens and individualized versus standard regimens for 
MDR-TB.  To advance TB diagnostics, USAID is performing systematic reviews to initiate 
diagnostic clinical trials and identify gaps that limit progress on policies.  USAID also is 
developing models to determine the best use of current tools to maximize case detection based 
on the current epidemiology of TB, available health systems and existing capacity.  USAID is 
conducting operational and evaluation research at the country level to apply study results to 
actual practice in international settings.  CDC will take leadership of USAID’s infection control 
activities in the future. 
 
Based on overviews of four federal agencies, Dr. Sizemore emphasized that FTBTF partners 
ensure global coordination of TB control and research activities by creating domestic and 
international networks with public and private healthcare providers, academia, pharmaceutical 
companies, the Stop TB Partnership and WHO.  She was pleased to report that FTBTF is 
making tremendous progress on defining specific global TB control and research projects for 
implementation in the future. 
 
Drs. Castro, Cain and Sizemore provided additional details on the role of federal agencies in 
global TB control and research activities in response to specific questions raised by the ACET 
members. 
 
• The federal partners are continuing to use FTBTF as a forum to share data and closely 
collaborate.  This approach ensures that global TB control and research activities 
conducted by various federal agencies are complimentary and lessons learned are 
immediately disseminated to programs through technical assistance to enhance TB care 
and treatment in the field.  During the August 2009 FTBTF meeting, the federal partners 
will primarily discuss additional mechanisms, such as a website or listserve, to enhance 
information exchange among their respective agencies.  The new FTBTF website will be 
open to the public to ensure transparency to TB advocates, stakeholders, constituents 
and the TB community at large. 
• The Office of the U.S. Global AIDS Coordinator is continuing to serve on FTBTF and has 
expressed a strong interest in devoting a portion of its resources to the public health 
evaluation of global TB control and research activities. 
• The public can monitor funding of global TB research activities through the Treatment 
Action Group’s tracking system and the up-to-date clinical trials registration system that 
is supported by NIH, WHO and several other groups. 
 
ACET commended the Gates Foundation and NIH on their roles as the top two leading funders 
in global TB research.  Dr. Fleenor apologized that time did not permit ACET to engage in a 
more extensive discussion to make substantive comments and suggestions on the new CPTR 
Initiative or the role of federal agencies in global TB control and research activities.  However, 
he confirmed that ACET would discuss these issues in more detail during the October 2009 
meeting to formulate formal recommendations.  
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Dr. Damian Gessler 
 
Dr. Damian Gessler is a Semantic Web Architect at the University of Arizona.  He explained that 
the prior vision for maintenance of TB data was to collect and genotype isolates from every TB 
case in the United States to develop the Universal Genotyping Program.  The prior vision was 
enhanced to achieve the current vision of making data web-accessible and developing TB-
GIMS.  The TB community now recognizes the need to advance the current vision to achieve a 
future vision in which web-accessible data entered into TB-GIMs will be archived, sequenced, 
integrated and presented to facilitate the development of NTBA. 
 
A study published in Science in March 2006 provided solid evidence to support the need to 
create the nation’s first comprehensive and integration information and biological resource for 
an infectious disease.  The study documented the important role of archiving in three major 
areas.  Archiving formalizes the systematic collection and preservation of etiologic agents that 
cause disease in communities.  Archiving enables future technologies to be retroactively applied 
for a comprehensive and temporarily complete baseline.  Archiving has the ability to ground 
evidence-based decision-making on persistent data. 
 
The 2006 study was later supported in a February 2009 press release.  Illumina, Inc. presented 
a development roadmap for scaling its genome analyzer and noted that innovations would 
substantially increase output, decrease cost and expand applications.  Illumina estimated that 
coverage of a human genome with these developments would cost <$10,000 in 2009. 
 
As of February 2009, a 20-gigabyte single run on human data was achieved in three to seven 
days at a cost of $30,000-$50,000.  For M.tb, genome sequencing at 4.4Mbp would be required 
at least 12 times with the Illumina high throughput technology.  At 20 times the coverage, a 95-
gigabyte single run would yield ~1,100 genomes at an expected cost of $10,000 per run using 
bar code multiplexing.  The approximate raw cost of $9.26 per genome was based on a cost of 
$10,000 per run.  Each new TB case could be sequenced for ~$120,000 with raw sequencing. 
 
Emphasis is placed on the three components of integration in the current era of limited 
resources and the need to rapidly make decisions.  Integration is needed across genomic, 
phylogenetic, clinical and epidemiological data.  Actionable intelligence is needed to facilitate 
timely delivery of information for discriminatory decision-making.  Evidence-based decision-
making is needed to facilitate efficient allocation of resources for targeted preparation and 
effective response. 
 
NTBA would be implemented by placing isolates states previously submitted to the Universal 
Genotyping Program into an archival system that is professionally managed.  The isolates 
would be sequenced to build a population-based biological repository.  The sequences would be 
annotated into epidemiological and clinical data.  NTBA would be successful because unlike 
HIV, hepatitis C, influenza or other infectious diseases, the existing TB infrastructure to gather 
isolates or collect epidemiological and clinical data is superb. 
Update on the National TB Archive (NTBA) 
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The ongoing intelligence and value of NTBA at the local level would provide an incentive for 
physicians, nurses and TB controllers to submit isolates and for researchers, policymakers and 
communities to advocate for policy changes.  NTBA ultimately would lead to the collection of 
important genomic, phylogenetic, clinical and epidemiologic data and serve as a new approach 
to TB control in the 21st century. 
 
Dr. Gessler presented a series of maps to illustrate the capacity of NTBA in pinpointing 
locations of H1N1 influenza virus outbreaks and identifying areas to enhance TB contact 
investigations with geographic information systems at the local level.  He concluded that NTBA 
has a simple design of integrating biological and informatic resources under a national and 
coordinated scope.  Moreover, NTBA allows for spatial integration of contact investigations at 
local and trans-jurisdictional levels and also facilitates temporal integration by utilizing existing 
repositories to build a record and baseline data for the future. 
 
NTBA encourages conceptual integration across science, medicine and public health and 
enables evidence-based decision-making that is responsive to local needs and requirements.  
The next steps to advance NTBA are to obtain recommendations, endorsement, refinement and 
direction from ACET and leverage collaborative relationships with federal, state and local 
agencies for actual implementation. 
 
Dr. Castro fully supported the concept of NTBA, but he was uncertain of the actual steps for 
implementation.  He emphasized the critical need to obtain input from TB controllers and 
affected communities on potential barriers to accessing NTBA’s epidemiologic data.  For 
example, California accounts for the most TB morbidity in the United States, but does not share 
the HIV status of TB patients with CDC or any other entity.  However, the collection of the HIV 
status of TB patients will be a crucial component of NTBA.  Dr. Castro further emphasized that 
in adherence to existing agreements with states, CDC would not release RVCT data without 
direction from TB controllers. 
 
Several ACET members were pleased with the possible abilities of NTBA, particularly its 
potential to strengthen knowledge on the mechanisms of TB drug resistance.  However, Dr. 
Fleenor agreed with Dr. Castro regarding the need to obtain feedback on major barriers to 
implementation of NTBA from a broader group of TB controllers. 
 
To facilitate this effort, Dr. Fleenor encouraged Drs. Gessler and Gary Simpson, of Texas Tech 
University Health Sciences Center, to open discussions with Mr. Phillip Griffin, the ACET liaison 
to NTCA.  Drs. Gessler and Simpson would be placed on future ACET agendas to provide 
updates on NTBA and report the outcomes of their conversations with NTCA.  Dr. Fleenor 
confirmed that ACET would take formal action on NTBA based on the outcomes of these 
updates. 
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Dr. Fleenor opened the business session by reviewing nine items that would require ACET’s 
formal action. 
 
ISSUE 1:  Dr. Fleenor entertained a motion for ACET to approve the previous meeting minutes, 
but he proposed a change in which attachments or addenda referenced on page 15 of the 
minutes would be deleted. 
 
A motion was properly placed on the floor and seconded by Mr. Kinney and Dr. Bakhtawar, 
respectively, for ACET to accept the previous minutes with the change Dr. Fleenor proposed for 
the record.  ACET unanimously approved the March 3-4, 2009 Draft Meeting Minutes as 
amended with no further discussion or changes. 
 
ISSUE 2:  The following motion was properly placed on the floor and seconded by Drs. Fleenor 
and Bakhtawar, respectively: 
 
 WHEREAS, access to care for all in the United States (US) is an admirable and 
desirable health policy goal; 
 
 WHEREAS, access to care for the treatment of TB is necessary to achieve 
health equity and assure the public’s health in the US; 
 
 WHEREAS, treatment of TB is the most effective way of interrupting transmission 
in a community; and 
 
 THEREFORE, ACET recommends that the Secretary of HHS advise executive 
and legislative branch health policymakers that any national health plan assuring 
unrestricted access to diagnosis and treatment of TB include: 
 
• Underinsured and uninsured US residents 
• Legal non-residents (e.g., students and work visa holders) 
• Undocumented aliens 
• Individuals undergoing repatriation to or from the US 
• Individuals entering the US under the Compact of Federal Free Association 
states 
 
ACET unanimously approved the motion for issue 2 with no further discussion. 
 
ISSUE 3:  The following motion was properly placed on the floor and seconded by Drs. 
Bakhtawar and Seaworth, respectively.  “ACET endorses the provisional Interferon Gamma 
Release Assay Guidelines to detect Mycobacterium Tuberculosis among persons in the United 
States and requests that CDC/DTBE publish these guidelines as soon a practicable.” 
 
ACET Business Session 
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ACET unanimously approved the motion for issue 3, but the members agreed to submit 
language to refine the section of the guidelines that advises against making decisions based on 
positive IGRA or TST results alone and recommends additional evaluation, including chest x-
rays or sputum smears.  ACET agreed to provide Dr. Bakhtawar with any additional comments 
on this section of the guidelines within the next two weeks. 
 
ISSUE 4:  The following motion was properly placed on the floor and seconded by Drs. Fleenor 
and Seaworth, respectively.  “ACET recommends that DTBE remain active participants on the 
NCHHSTP Workgroup for Persons Using Drugs and report its plans to ACET on incorporating 
specific interventions in its future programs for improving TB outcomes in this high-risk group.” 
 
ACET unanimously approved the motion for issue 4.  Dr. Fleenor confirmed that DTBE’s 
update on TB and substance abuse would be placed on the ACET agenda for the October 2009 
meeting or the first meeting in 2010. 
 
ISSUE 5:  The following motion was properly placed on the floor and seconded by Drs. 
Bakhtawar and Hahn, respectively.  “ACET recommends that DTBE approach industries hiring 
employees from countries under the Compact of Free Association, particularly the Federated 
States of Micronesia, Republic of the Marshall Islands and Republic of Palau, to perform post-
hire pre-employment TB screening.” 
 
The motion for issue 5 failed by a vote of 3 members opposed and 2 members in favor.  
ACET agreed that this issue would be revisited during the October 2009 meeting after Dr. 
Bakhtawar presented data to support the motion. 
 
ISSUE 6:  The following motion was properly placed on the floor and seconded by Drs. Seaworth 
and Hahn, respectively: 
 
 WHEREAS, HIV status is a critical value used in diagnostic and treatment 
decisions for the care of tuberculosis disease; and 
 
 THEREFORE, ACET requests that CDC/DGMQ recommend HIV testing in 
diagnostic requirements of all refugees and immigrants entering the United 
States who are assigned a “TB classification” during the overseas screening 
process. 
 
ACET unanimously approved the motion for issue 6 with no further discussion.  
 
ISSUE 7:  The following motion was properly placed on the floor and seconded by Mr. Jones and 
Dr. Hahn, respectively.  “ACET recommends that CDC, through DTBE or other sources at its 
disposal, allocate funds to allow distribution of the “TB Toolkit” for use in educating appropriate 
parties working with African Americans at risk for TB and for DTBE to subsequently evaluate the 
results.” 
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ACET unanimously approved the motion for issue 7.  In follow-up to the resolution, ACET 
asked DTBE to develop and present a concrete work plan and timeline to fund, disseminate and 
evaluate the TB Toolkit. 
 
ISSUE 8:  The following motion was properly placed on the floor and seconded by Drs. Fleenor 
and Hahn, respectively.  “ACET recommends that CDC ask the Office of the HHS Secretary to 
consider and approve the Association of State and Territorial Health Officials and the Council for 
State and Territorial Epidemiologists as new ACET liaison members.” 
 
ACET unanimously approved the motion for issue 8 with no further discussion.  
 
ISSUE 9:  The following motion was properly placed on the floor and seconded by Drs. Hahn and 
Seaworth, respectively.  “ACET recommends that DTBE send a Dear Colleague letter to state 
and local TB controllers to encourage proactive collaboration with their preparedness planning 
groups and other staff to plan for the fall influenza season and determine functions that could be 
managed by hiring temporary staff or contractors using supplemental pandemic influenza 
stimulus dollars instead of pulling key TB program staff during the influenza season.” 
 
ACET unanimously approved the motion for issue 9.  Dr. Castro confirmed that he would 
share the “Dear Colleague” letter with CDC staff members who are leading the pandemic 
influenza preparedness planning effort for broader distribution to their constituents. 
 
Dr. Fleenor led ACET in a review of the action items and future agenda items that were raised 
over the course of the meeting. 
 
 Action Items 
• Ms. Ann Cronin, of DTBE, will provide ACET with its comments that were given to Dr. 
Frieden in preparation of his presentation during the June 2009 NTCA meeting.  The 
written briefing to Dr. Frieden included current surveillance data in the context of TB 
elimination and DTBE’s concerns regarding existing capacity to eliminate TB. 
• Ms. Margie Scott-Cseh, the ACET Committee Management Specialist, will distribute 
DTBE’s TB-specific pandemic influenza operational plan to ACET. 
• Dr. Vernon will provide Ms. Katz with contact information for members of the American 
College Health Association who can serve as reviewers of the foreign-born guidelines. 
• Ms. Scott-Cseh will e-mail Dr. Reichler’s slides to ACET. 
 
Agenda Items 
• An overview of strategies local health departments implemented to maintain their core TB 
functions during the H1N1 influenza outbreak while personnel were deployed to the 
response. 
• Update by DTBE on its progress in responding to recommendations made by the African 
American Workgroup. 
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Dr. Fleenor opened the floor for public comments; no participants responded. 
 
 
 
 
 
The participants applauded Dr. Fleenor for his outstanding leadership and efficiency in resolving 
a large number of resolutions during the short time of the business session.  The next ACET 
meeting would be held on October 27-28, 2009 in Atlanta, Georgia. 
 
With no further discussion or business brought before ACET, Dr. Fleenor adjourned the meeting 
at 2:08 p.m. on July 15, 2009. 
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